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1. INTRODUCTION 
Arterial stiffness describes the rigidity of arterial wall and is one of the earliest 
detectable manifestations of adverse structural and functional changes within 
vessel wall (Laurent et al. 2006). Arterial stiffening increases the left ventricular 
afterload and promotes development of left ventricular hypertrophy (Toprak et 
al. 2009). Moreover, arterial stiffening leads to reduction in diastolic blood 
pressure (BP), thus diminishing coronary perfusion (O’Rourke 2008, Milan et 
al. 2011) and causes unbalanced myocardial demand/coronary perfusion pre-
disposing to ischaemia (Mottram et al. 2005). Arterial stiffness is also asso-
ciated with atherosclerosis in different vascular beds (Van Popele et al. 2001; 
Boutouyrie et al. 2002; Agabiti-Rosei and Muiesan 2007b). Aortic pulse wave 
velocity (aPWV) is considered the „gold standard” parameter of arterial stiff-
ness. The aPWV has an independent predictive value for cardiovascular (CV) 
events and all-cause mortality in high-risk patients and in general population 
(Laurent et al. 2003; Vlachopoulos et al. 2010). Current European guidelines 
for management of arterial hypertension introduce assessment of arterial 
stiffness by aPWV as an index of subclinical target organ damage (Mancia et al. 
2007).  
Vascular calcification (VCa) results from the deposition of calcium 
hydroxyapatite in the blood vessels (Demer and Tintut 2008). Experimental and 
clinical evidence indicate that VCa is an actively regulated process that involves 
a complex interplay between the promoters and inhibitors of calcification 
(Johnson et al. 2006). There is evidence that VCa might contribute to the 
increase in arterial stiffness (Sigrist et al. 2007), and vice versa (Dao et al. 
2005). In chronic kidney disease, strong cross-sectional relationship has been 
demonstrated between VCa and aortic stiffness (Guerin et al. 2000; Verbeke et 
al. 2010). The VCa is an important contributor to CV morbidity and mortality in 
patients with advanced atherosclerosis (Alexopoulos and Raggi 2009), diabetes 
mellitus (Olson et al. 2000) and chronic kidney disease (Johnson et al. 2006).  
Osteoprotegerin (OPG) is an inhibitor of calcification, which has been 
considered as a possible link between bone metabolism and vascular disease 
(Schoppet et al. 2002). Animal models indicate that OPG has disparate effects 
within the bones and the arteries. In genetic knockout animal models, OPG 
deficiency leads to medial calcification of the aorta and renal arteries (Bucay et 
al. 1998). In contrast, human studies have shown positive association between 
serum OPG levels and CV disease. Elevated serum OPG levels have been 
associated with coronary artery disease (CAD), diabetic complications, VCa 
and CV mortality (Kiechl et al. 2006; Anand et al. 2007; Van Campenhout and 
Golledge 2009).  
Osteopontin (OPN) is also an inhibitor of VCa (Scatena et al. 2007). Serum 
OPN deficiency is related to ectopic calcification in animal models (Steitz et al. 
2002). However, OPN levels are positively correlated with severity of aortic 
calcification in haemodialysis patients (Barreto et al. 2011). The OPN is 
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abundantly expressed in atherosclerotic plaques, and stimulates recruitment of 
macrophages and production of inflammatory cytokines (Scatena et al. 2007). 
Serum OPN level is related to presence and extent of CAD (Ohmori et al. 2003) 
and is an independent predictor of adverse CV events in patients with chronic 
stable angina (Minoretti et al. 2006). 
Vitamin D is another important regulator of VCa. The effects of vitamin D 
on VCa appear to follow a biphasic pattern, with both excess and deficiency 
promoting its development (Shroff et al. 2008a). Low levels of 25-hydro-
xyvitamin D (25(OH)D) are associated with extensive VCa (Garcia-Canton et 
al. 2011) and injection of activated vitamin D increases survival in patients with 
end-stage renal disease (Teng et al. 2005). On the other hand, treatment with 
vitamin D increases aortic calcification in animal models (Niederhoffer et al. 
1997). Moreover, recent data indicate that 1,25-dihydroxyvitamin D 
(1,25(OH)2D) downregulates the renin-angiotensin system (Li et al. 2002) and 
reduces proinflammatory cytokine secretion (Giulietti et al. 2007).  
Inflammation plays a key role in development and progression of athero-
sclerosis. Several studies have demonstrated the association of various markers 
of inflammation, including acute phase reactants, cytokines and cellular 
adhesion molecules, with manifestations of atherosclerotic vascular disease. 
Elevated C-reactive protein (CRP) has been shown to be useful for predicting 
the risk of CV events in patients with established CAD (Heslop et al. 2010) and 
in asymptomatic individuals (Ridker et al. 1997). Soluble intercellular adhesion 
molecule-1 (sICAM) is a marker of presence and severity of atherosclerosis 
(Pradhan et al. 2002) and predicts myocardial infarction in apparently healthy 
men (Ridker et al. 1998). The β2-microglobulin (β2M) has recently emerged as a 
novel marker of inflammation (Wilson et al. 2007). Plasma β2M is increased in 
patients with autoimmune diseases, infections and atherosclerosis (Wilson et al. 
2007; Shinkai et al. 2008). A recent population-based study has demonstrated 
that β2M is an independent predictor of all-cause mortality in elderly subjects 
(Shinkai et al. 2008). 
High-grade oxidative stress (OxS) is another important contributor to athero-
sclerosis and CV mortality. Severe OxS promotes endothelial dysfunction 
(Heitzer et al. 2001), arterial stiffening (Kals et al. 2006b), proliferation and 
migration of vascular smooth muscle cells (VSMC) and activation of matrix 
metalloproteinases (Hulsmans et al. 2010). Oxidized low-density lipoprotein 
(oxLDL) is a marker of OxS, which is associated with presence of athero-
sclerotic lesions in the coronary arteries, the carotid artery and the arteries of the 
lower extremity (Madamanchi et al. 2005). 
Peripheral arterial disease (PAD) is a highly prevalent public health problem 
associated with major detrimental effects on quality of life, being the main 
cause of limb amputation. Furthermore, patients with the diagnosis of PAD are 
at high risk of myocardial infarction, stroke and CV death (Hirsch et al. 2007). 
Calcified atherosclerotic arteries (Niskanen et al. 1990), increased arterial 
stiffness (Kals et al. 2006a), high-grade OxS (Haslacher et al. 2011) and 
4
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inflammation (Tzoulaki et al. 2005; Urbonaviciene et al. 2011) might influence 
the clinical course of PAD. However, data about the association between these 
parameters in patients with PAD are limited. The main aim of the present thesis 
was to investigate the relationship between arterial stiffness (functional profile), 
VCa and angiographic score (AngSc) (structural profile), OxS and inflam-
mation (biochemical profile) in patients with symptomatic PAD and in 
clinically healthy subjects. We chose to investigate patients with PAD as it is a 
manifestation of systemic atherosclerosis that involves not only arteries of the 
lower extremities but also coronary, cerebral and renal vascular beds. 
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2. REVIEW OF THE LITERATURE 
2.1. Arterial stiffness and cardiovascular disease 
Arterial stiffness has been known as a sign of CV disease since the 19th century 
(Roy 1881). However, the clinical utility of arterial stiffness has only emerged 
in recent time. Nowadays, arterial stiffness can be accurately measured by a 
range of non-invasive techniques and it is established as a predictor of adverse 
CV outcome in high-risk patients (Boutouyrie et al. 2002; Cruickshank et al. 
2002) and in general population (Laurent et al. 2006). Current European guide-
lines for the management of arterial hypertension indicate that increased aPWV 
indicates target organ damage and predicts high CV risk (Mancia et al. 2007). 
Recently, the reference values of aPWV have been published (Boutouyrie and 
Vermeersch 2010), which facilitates the use and interpretation of aPWV in 
clinical practice. 
 
 
2.1.1. Determinants of arterial stiffness 
Large arteries have two interrelated haemodynamic functions. First, they 
function as a conduit to deliver adequate blood supply from the heart to peri-
pheral tissues. Second, large arteries dampen the pressure oscillations that result 
from intermittent ventricular ejection ensuring peripheral organ perfusion at 
steady flow and pressure (London and Pannier 2010). The efficiency of this 
function depends on the elastic properties of arterial wall. 
Arterial wall consists of three layers: the intima (including the endothelium), 
the media and the adventitia. Each of these layers has specific roles in the 
regulation of arterial stiffness. Endothelial cells synthesize nitric oxide (NO) 
and endothelin-1, which are involved in the regulation of arterial stiffness 
(McEniery et al. 2003; Schulz et al. 2011). The NO reduces arterial stiffness via 
its vasodilatatory activity and inhibitory activity against VSMC growth (Cai and 
Harrison 2000; Simionescu 2007). The medial layer consists of elastic fibres, 
VSMC and the extracellular matrix. In aorta, elastic fibres are gathered together 
in sheets arranged in concentric layers throughout the thickness of the media 
(Shirwany and Zou 2010). The adventitia consists of collagen, extracellular 
matrix components, fibroblasts and vasa vasorum. Collagen fibres are approxi-
mately 500 times stiffer than elastic fibres; therefore, they are one of the major 
determinants of arterial stiffness (Nichols and O’Rourke 1998). Thus, arterial 
stiffness is influenced by endothelial function, VSMC tone and the relative 
content of elastin and collagen fibres (Astrand et al. 2011).  
Increased arterial stiffness has been associated with a number of CV risk 
factors. Age is one of the most important determinants of arterial stiffness 
(Ahlgren et al. 1997; McEniery et al. 2005). Throughout life, arteries are 
subjected to a great number of cycles of stress, which leads to progressive 
degeneration of arterial wall. Age-related remodeling leads to gradual increase 
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in arterial stiffening through fatigue fracture and degradation of elastin fibres 
and increased loading on collagen fibres (McEniery et al. 2005; O’Rourke and 
Hashimoto 2007). The BP is another important determinant of arterial stiffness. 
Hypertension causes fractures and fragmentation of elastic lamellae, as well as 
increases collagen and calcium content in arterial wall (Benetos et al. 1993; 
Avolio et al. 1998). Diabetes mellitus also contributes to arterial stiffening 
(Heilman et al. 2009a; Llaurado et al. 2012). In diabetic patients, accumulation 
of advanced glycation end products in arterial wall promotes development of 
arterial stiffness through impairment of endothelial function (Rojas et al. 2000) 
and promotion of inflammation (Wendt et al. 2006). Other important determi-
nants of arterial stiffness include dyslipidemia (Wilkinson et al. 2002), smoking 
(Mahmud and Feely 2003) and sedentary lifestyle (Tanaka et al. 1998). 
 
 
2.1.2. Measures of arterial stiffness and their predictive value 
Various methodologies and indices are used to assess arterial stiffness. Non-
invasive methods for assessment of arterial stiffness are based on 1) change in 
vessel diameter or lumen area due to the change in distending pressure (local 
arterial stiffness), 2) estimation of PWV (regional arterial stiffness), 3) pulse 
wave analysis (PWA) (wave reflection) (Sakuragi and Abhayaratna 2010). 
 
2.1.2.1. Local arterial stiffness 
Local arterial stiffness is usually determined from the superficial arteries, 
mainly the brachial, femoral and the carotid arteries. Assessment of local stiff-
ness is based on the measurement of change in vessel size in relation to the 
change in distending pressure. Local pulse pressure should be measured at the 
site of distension measurement. The use of brachial BP in calculation of these 
indices may introduce systematic errors, particularly in younger subjects in 
whom peripheral pulse pressure (PPP) is significantly higher than central pulse 
pressure (CPP). Local arterial stiffness can be measured using echo-tracking 
techniques, applanation tonometry or magnetic resonance imaging (Resnick et 
al. 1997; Turesson et al. 2005; Laurent et al. 2006). Evaluation of local arterial 
stiffness requires good technical experience and longer time to detect very small 
changes in arterial diameter, hence this method is unsuitable for large epidemio-
logical studies. 
 
2.1.2.2. Regional arterial stiffness (pulse wave velocity) 
The PWV is a measure of regional arterial stiffness. Measurement of PWV is 
generally accepted as the most simple, robust and reproducible method to 
determine arterial stiffness (Laurent et al. 2006). The PWV is calculated as the 
distance travelled by the pulse wave divided by the time taken to travel the 
17 
distance (Laurent et al. 2006) (Figure 1). Accurate PWV quantification is 
dependent on accurate measurement of the distance between recording sites 
(Van Bortel et al. 2012). Readings from the two sites are taken simultaneously 
or separate readings are gated to a fixed point in the cardiac cycle, usually the R 
wave in electrocardiography (ECG) (Laurent et al. 2006). Pulse waves can be 
detected by applanation tonometry, Doppler ultrasound or by magnetic reso-
nance imaging (Laurent et al. 2006; Redheuil et al. 2010). Transit time is 
usually measured from the foot of the wave using the point of intersecting 
tangents from the decline of the previous pulse and the sharp upstroke of the 
following pulse.  
 
Figure 1. Measurement of aPWV with the foot to foot method (Adji et al. 2011, 
modified).  
 
 
The PWV can be measured from the central and peripheral arteries. However, it 
is well known that aortic pressure is the major determinant of left ventricular 
afterload (Laurent et al. 2006). Therefore, aPWV is the most clinically relevant 
index of arterial stiffness, since it measures the propagation of pulse wave along 
the aorta and iliac artery. Accordingly, aPWV increases exponentially with 
aging and is a sensitive indicator of arterial stiffness after the age of 50 to 60 
years, whereas brachial pulse wave velocity (bPWV) does not increase with 
aging (McEniery et al. 2005). Moreover, it has been demonstrated that bPWV 
or femoro-tibial PWV has no predictive value in patients with end-stage renal 
5
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disease. In contrast, aPWV was an independent predictor of CV mortality in 
these patients (Pannier et al. 2005).  
An increasing number of studies have demonstrated the accuracy of PWV as 
an independent predictor of CV morbidity and mortality in patients with 
different co-morbidities and CV risk. Several longitudinal studies have shown 
that aPWV is an independent predictor of all-cause and CV mortality in high-
risk patients, such as those with hypertension (Laurent et al. 2001), diabetes 
mellitus (Blacher et al. 2012) and end-stage renal disease (Blacher et al. 1999). 
In addition, increased aPWV predicts CV mortality in general population 
(Shokawa et al. 2005; Willum-Hansen et al. 2006; Inoue et al. 2009). The 
results of a recent meta-analysis indicate that aortic stiffness is strongly related 
to CV events, independent of age, BP and other risk factors of CV disease 
(Vlachopoulos et al. 2010). 
 
2.1.2.3. Wave reflection (pulse wave analysis) 
Central PWA provides information about wave reflection. Ventricular ejection 
generates the forward pressure wave that travels to the periphery along the 
arterial tree. The pressure wave is reflected from the periphery, mainly at branch 
points or sites of impedance mismatch (Laurent et al. 2006). The reflected wave 
is superimposed on the forward pressure wave. In elastic arteries, PWV is low 
and the reflected waves arrive at the aortic root during diastole, which improves 
coronary blood flow. In stiff arteries, PWV is increased and the reflected waves 
arrive at the ascending aorta earlier, adding to the forward wave and 
augmenting the systolic pressure (Mottram et al. 2005). The forward and reflec-
ted pressure waves can be quantified through the augmentation index (AIx), 
which is defined as the difference between the second and the first systolic 
peaks expressed as a percentage of pulse pressure (Figure 2) (Mackenzie et al. 
2002). As AIx is influenced by the timing of the reflected wave, the distance to 
the reflecting sites and the amplitude of the reflected wave, it is an indirect 
measure of arterial stiffness (Nichols and O’Rourke 1998; Safar et al. 2003).  
The main determinants of AIx include heart rate, height, age, mean arterial 
pressure (MAP) and PWV (Lemogoum et al. 2004; Agabiti-Rosei et al. 2007a). 
It is well established that AIx is inversely related to heart rate (Agabiti-Rosei et 
al. 2007a). With increase in heart rate, ejection time is shortened. Therefore, 
reflected waves can have less effect on late systolic pressure and more effect on 
the diastolic part of the pulse wave (Nichols and O’Rourke 1998). In addition, 
AIx is inversely associated with height. Hence, AIx is normally higher in 
women than in men (McEniery et al. 2005). Age is an important determinant of 
wave reflections. It has been shown that AIx increases almost linearly with age 
up to the age of 60 years; however, only minimal rise in AIx is observed after 
the age of 65 years (Mitchell et al. 2004; McEniery et al. 2005). As increased 
central arterial stiffness and peripheral vascular resistance are associated with an 
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increase in PWV and shifting of the reflection site in the proximal direction, 
they elevate AIx (Nichols 2005; Adji et al. 2011). 
 
 
Figure 2. Pulse wave analysis (Adji et al. 2011, modified). Augmentation index 
is calculated from the ratio of augmentation pressure to pulse pressure and is 
expressed in percentages. 
 
 
From PWA, also central BP can be derived. In young subjects, central systolic 
BP (CSBP) is significantly lower than peripheral systolic BP (PSBP), whereas 
diastolic BP remains approximately constant throughout the arterial tree 
(Agabiti-Rosei et al. 2007a). This phenomenon is called pulse pressure ampli-
fication. However, an age-related increase in arterial stiffness attenuates the 
difference between CPP and PPP (Wilkinson et al. 2001; McEniery et al. 2008). 
Assessment of central BP is of clinical importance, because central rather than 
peripheral BP affects directly the function of target organs (Agabiti-Rosei et al. 
2007a; Kampus et al. 2011).  
The prognostic value of central BP and AIx has been documented in several 
studies. Elevated AIx is independently associated with increased risk of 
restenosis, myocardial infarction and mortality in patients undergoing percuta-
neous coronary interventions (Weber et al. 2005). In patients with end-stage 
renal disease, AIx is a strong predictor of all-cause and CV mortality (London 
et al. 2001). The same study group has shown that CPP predicts independently 
all-cause mortality in haemodialysis patients. In contrast, PPP had no predictive 
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value for mortality after adjustment for CV risk factors (Safar et al. 2002). 
Similarly, higher CSBP but not measures of peripheral BP independently 
predicts CV mortality in elderly individuals (Pini et al. 2008). 
 
 
2.1.3. Arterial stiffness and atherosclerosis 
The relationship between arterial stiffness and atherosclerosis has been 
investigated in numerous studies. Animal experiments indicate that presence of 
atherosclerosis may increase arterial stiffness. Indeed, extensive atherosclerotic 
lesions in the aorta were associated with aortic stiffening in apolipoprotein  
E-deficient mice (Wang et al. 2000). Moreover, in monkeys, atherogenic diet 
significantly increased aPWV, whereas cholesterol regression diet led to a 
decrease in aPWV (Farrar et al. 1991). 
Human studies confirm the results of animal experiments. Results from a 
longitudinal study demonstrate that aPWV is an independent predictor of 
coronary events in patients with essential hypertension (Boutouyrie et al. 2002). 
In addition, large artery stiffness contributes to exercise induced myocardial 
ischaemia (Kingwell et al. 2002) and predicts outcome after coronary inter-
ventions in patients with CAD (Duprez and Cohn 2007). In general population, 
aortic stiffness is strongly associated with presence of plaques in the carotid 
artery and in the aorta (Van Popele et al. 2001). It has been shown that patients 
with PAD have stiff arteries (Kals et al. 2006a). Moreover, arterial stiffening is 
related to decreased ankle-brachial pressure index (ABPI) in elderly subjects 
(Lind 2011). However, there is no data regarding the potential association of 
aortic stiffness with angiographic severity grade of atherosclerosis in patients 
with PAD. In Paper IV of the present thesis, we evaluated the relationship of 
aPWV with AngSc in patients with symptomatic PAD.  
 
 
2.2. Vascular calcification 
Ectopic calcification in the vasculature has been noted for many decades (Frink 
et al. 1970). There are two distinct patterns of VCa: calcification of the media 
(arteriosclerosis) and calcification of the intima (atherosclerosis). Previous 
studies indicate that in patients with atherosclerosis mostly intimal calcification 
is seen (Verbeke et al. 2010). Intimal calcification is associated with the infilt-
ration of vessel wall with T cells and macrophages and shows the distinguishing 
features of endochondral ossification (Vattikuti and Towler 2004; Johnson et al. 
2006). On the other hand, medial calcification is associated with diabetes 
mellitus, end-stage renal disease and aging (Sutliff et al. 2011). This type of 
calcification is characterized by intra-membranous ossification. The VCa could 
be assessed by biomarkers or by instrumental techniques (e.g. computed tomo-
graphy (CT)).  
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2.2.1. Biomarkers of vascular calcification 
Until recently, VCa was simply viewed as passive deposition of hydroxyapatite 
in arterial wall. Accumulating evidence now points to a tightly regulated 
process, with competition between the factors promoting and inhibiting calci-
fication (Ketteler et al. 2011). The OPG, OPN and fetuin-A are important 
inhibitors of VCa that are implicated in the pathogenesis of atherosclerosis 
(Isoda et al. 2002; Jono et al. 2010; Ix et al. 2011). 
 
2.2.1.1. Osteoprotegerin, osteopontin and fetuin-A 
The OPG is a glycoprotein that belongs to the tumour necrosis factor receptor 
superfamily of cytokines. The OPG is a decoy receptor that inhibits osteoclast 
differentiation and activation (Lacey et al. 1998). Animal experiments indicate 
that OPG might be a possible link between bone metabolism and CV disease. In 
a mouse model, deficiency of OPG resulted in severe osteoporosis and VCa 
(Bucay et al. 1998). Moreover, OPG inhibits progression of atherosclerotic 
plaques by preventing an increase in lesion size and lesion calcification in mice 
(Bennett et al. 2006). 
In contrast to the apparent protective role of OPG observed in animal 
models, observational studies in patients have demonstrated positive relation-
ship between serum levels of OPG and CV disease (Kiechl et al. 2004; Anand 
et al. 2006; Rasmussen et al. 2006). Moreover, increased OPG levels have been 
reported in patients with CAD, carotid atherosclerosis, stroke, heart failure and 
hypertension (Browner et al. 2001; Kiechl et al. 2006; Blazquez-Medela et al. 
2011). In patients with symptomatic PAD, serum levels of OPG are positively 
correlated with severity of atherosclerosis (Ziegler et al. 2005) and with 
endothelial dysfunction (Golledge et al. 2008).  
Apart from influencing endothelial function, OPG is also implicated in 
arterial stiffening. It has been shown that OPG is positively correlated with 
brachial-ankle pulse wave velocity (baPWV) in haemodialysis patients (Talib et 
al. 2011; Nakashima et al. 2011) and in patients with type 2 diabetes mellitus 
(Kim et al. 2005; Jung et al. 2010). Moreover, several studies have shown that 
higher serum OPG levels are independently associated with aPWV in patients 
with chronic kidney disease (Scialla et al. 2011; Ford et al. 2012) and in general 
population (Schnabel et al. 2008).  
The OPN is another important inhibitor of VCa. The OPN is a glycoprotein 
that is expressed in osteoblasts, osteocytes, VSMC and endothelial cells (Den-
hardt et al. 2001). It directly inhibits calcification by binding to hydroxyapatite 
(Wada et al. 1999) and by inducing decalcification (Asou et al. 2001). The OPN 
might be involved in regulation of inflammation (Giachelli and Steitz 2000). 
Indeed, OPN is produced in activated T cells and macrophages (Ramaiah and 
Rittling 2008) and its levels are elevated in inflammatory diseases (Wong et al. 
2005; Agnholt et al. 2007). Moreover, OPN could contribute to progression of 
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atherosclerosis (Isoda et al. 2003). Expression of OPN correlates with amount 
of inflammatory cells (Isoda et al. 2002) and calcium deposits (Fitzpatrick et al. 
1994) in atherosclerotic plaques. In addition, OPN has emerged as a marker of 
increased CV risk. In patients with CAD, plasma OPN levels are significantly 
associated with presence and extent of CV disease independently of traditional 
risk factors (Ohmori et al. 2003). Moreover, plasma OPN levels are indepen-
dent predictors of restenosis after percutaneous coronary intervention (Kato et 
al. 2006). 
Previous research suggests that OPN might be implicated in arterial stiffe-
ning. In mice, overexpression of OPN is associated with thickening of the aorta 
(Chiba et al. 2002). Moreover, elevated OPN levels are independently asso-
ciated with increased aortic stiffness in patients with rheumatoid arthritis 
(Bazzichi et al. 2009).  
Fetuin-A is a glycoprotein which acts as a potent inhibitor of VCa. Fetuin-A 
binds calcium phosphate and calcium carbonate and inhibits the process of 
matrix mineralization (Schinke et al. 1996). Both animal models and human 
studies indicate that fetuin-A deficiency is associated with increased VCa. 
Indeed, fetuin-A knockout mice develop higher soft tissue calcification than 
wild-type mice (Schäfer et al. 2003). Furthermore, lower levels of fetuin-A are 
significantly associated with greater extent of valvular (Wang et al. 2005) and 
coronary (Koos et al. 2009) calcification in patients with chronic kidney 
disease. In addition, fetuin-A levels are inversely related to severity of coronary 
artery calcification in subjects free from clinical CV disease (Ix et al. 2011). 
Fetuin-A is not only a potent inhibitor of ectopic calcification but it also 
influences inflammatory response (Reynolds et al. 2005; Wang et al. 1997). It 
has been shown that fetuin-A inhibits the production of proinflammatory 
cytokines (Kelly and Smith 1997) and is inversely correlated with CRP levels in 
dialysis patients (Wang et al. 2005). The data regarding the association of 
fetuin-A with arterial stiffness is limited. Recent research indicates that fetuin-A 
is inversely related to baPWV in haemodialysis patients (Talib et al. 2011). In 
addition, decreased fetuin-A is independently associated with aortic stiffening 
in patients with chronic kidney disease (Ford et al. 2010) and in patients with 
normal kidney function (Roos et al. 2009).  
In the present thesis, we investigated the possible relationship of aPWV with 
OPG (Paper I), fetuin-A (Paper II) and OPN (Paper IV) in PAD patients and in 
clinically healthy subjects. 
 
2.2.1.2. Vitamin D 
Vitamin D is classically known for its crucial role in calcium and bone 
metabolism (Bouillon et al. 2008). There exist two major forms of vitamin D: 
vitamin D3, which is mainly derived by way of synthesis in the skin and from 
animal sources, and vitamin D2 (ergocalciferol), which is derived from plants 
(Zilmer et al. 2010). Vitamin D as a precursor exerts no significant biological 
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activity. First, vitamin D is hydroxylated to 25(OH)D in the liver. Then, the 
enzyme 1α-hydroxylase converts 25(OH)D to 1,25(OH)2D. The kidney is the 
major site for production of circulating 1,25(OH)2D (Zilmer et al. 2010). 
An accumulating body of evidence suggests that vitamin D may be impli-
cated in the pathogenesis of CV disease (Zittermann et al. 2005; Norman and 
Powell 2005; Brewer et al. 2011). Vitamin D receptors are present in VSMC, 
endothelial cells, myocardiocytes, macrophages and lymphocytes (Landry et al. 
2011). The influence of vitamin D in these tissues could have important 
implications for vascular function and disease. Several studies have reported 
lower 25(OH)D levels in patients with cerebrovascular disease (Cigolini et al. 
2006; Poole et al. 2006), CAD (Scragg et al. 1990), heart failure (Zittermann et 
al. 2003), hypertension (Forman et al. 2007) and diabetes mellitus (Martins et 
al. 2007). Moreover, low vitamin D status has also been associated with 
subclinical (Melamed et al. 2008b) and clinical PAD (Fahrleitner et al. 2002).  
The relationship between vitamin D and VCa remains controversial. On the 
one hand, deficiency of vitamin D is associated with VCa in patients with 
chronic kidney disease (Garcia-Canton et al. 2011). On the other hand, vitamin 
D toxicity is associated with increased VCa in animal models (Henrion et al. 
1991; Norman and Powell 2005).  
There have been relatively few studies examining the association between 
vitamin D and arterial stiffness. Low 25(OH)D levels are significantly 
associated with increased baPWV in patients with type 2 diabetes mellitus (Lee 
et al. 2012). In addition, several studies have demonstrated that serum 25(OH)D 
is inversely related to aPWV in apparently healthy subjects (Al Mheid et al. 
2011; Salum et al. 2011) and in general population (Mayer et al. 2011). In a 
longitudinal study, supplementation of 25(OH)D significantly decreased aPWV 
in adolescents (Dong et al. 2010).  
In the present thesis, we investigated the possible relationship between 
25(OH)D and aortic calcification in PAD patients and in clinically healthy 
subjects (Paper III). Moreover, we evaluated the association between ABPI and 
the composite measure of aPWV and 25(OH)D in PAD patients (Paper III).  
 
 
2.2.2. Measurement of vascular calcification  
by computed tomography 
Several imaging techniques have been developed for visualization and composi-
tional characterization of VCa. Electron beam CT and multi-slice CT are pre-
sently considered the „gold standard” for assessing the extent of VCa and its 
progression (Bellasi and Raggi 2007). The CT is a non-invasive, sensitive 
method of detecting VCa (Rumberger et al. 1995). The advantages of CT 
techniques include rapid acquisition of images, prevention of image blurring 
and accurate visualisation of small calcific deposits without utilising contrast 
media (Fuseini et al. 2003) (Figure 3). However, there are also substantial 
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limitations to these technologies. The CT techniques cannot differentiate intimal 
and medial calcification. Moreover, CT technologies are expensive and provide 
substantial exposure to ionized radiation (Bellasi and Raggi 2007). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A cross-section of the abdomen illustrating (A) non-calcified aortic wall, (B) 
calcification within the aortic wall as detected by CT (Paper III). 
 
 
2.2.3. Vascular calcification and arterial stiffness 
Previous research suggests that intimal and medial calcification are differently 
associated with arterial stiffness. The relationship between intimal calcification 
(atherosclerosis) and arterial stiffness remains unclear (Mackey et al. 2007). In 
contrast, several studies have demonstrated that arterial stiffness is inde-
pendently associated with medial artery calcification (arteriosclerosis), which is 
common in diabetes, chronic kidney disease, hypertension and aging (Iribarren 
et al. 2000; Davies and Hruska 2001; Guerin et al. 2008). Thus, strong cross-
sectional relationship has been demonstrated between VCa and aortic stiffness 
in patients with chronic kidney disease (Guerin et al. 2000; Verbeke et al. 
2010). Moreover, rapid progression of VCa is associated with arterial stiffening 
and increased mortality in patients with impaired renal function (Sigrist et al. 
2007). Furthermore, aortic calcification is independently related to aortic 
stiffening in patients with isolated systolic hypertension (McEniery et al. 2009). 
However, the relationship between aortic calcification and stiffness in patients 
with PAD has not been studied. In Paper III of the present thesis, we aimed to 
investigate the association of aortic calcification with aPWV in subjects with 
symptomatic PAD and in clinically healthy individuals. 
 
 
2.2.4. Vascular calcification and cardiovascular outcome 
Both calcification within atherosclerotic plaque and diffuse medial calcification 
increase the risk of adverse CV events. It has been shown that atherosclerotic 
calcification may contribute to dissection after balloon angioplasty (Fitzgerald 
et al. 1992). The role of calcification in the process of atherosclerotic plaque 
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rupture is unclear. On the one hand, plaque calcification destabilizes a plaque, 
specifically in the areas of interface between hard and soft tissues (Virmani et 
al. 1998). On the other hand, other investigations have suggested that calcified 
plaques are more stable and less prone to rupture (Ge et al. 1999). 
Medial artery calcification is also an important determinant of CV outcome. 
Indeed, abdominal aortic calcification is an independent predictor of mortality 
and nonfatal CV events in dialysis patients (London et al. 2003; Verbeke et al. 
2011). Furthermore, in patients with diabetes, medial artery calcification is 
strongly correlated with CAD and adverse CV events (Niskanen et al. 1994; 
Olson et al. 2000). It has also been demonstrated that the magnitude of medial 
artery calcification of the femoral artery is a risk factor for amputation in 
patients with PAD (Lehto et al. 1996). 
 
 
2.3. Inflammation 
Inflammation has been recognised as a crucial factor for development and 
progression of atherosclerosis (Ridker et al. 1997; Ross 1999). At early stages 
of atherosclerosis endothelial cells begin to express adhesion molecules on their 
surface, which facilitates the recruitment of monocytes and T-lymphocytes and 
their attachment to the endothelium. (Badimon et al. 2011). Monocytes and  
T-lymphocytes that had adhered to the endothelium penetrate into the intima. 
Local inflammatory response stimulates the transformation of monocytes into 
macrophages. Increase in the permeability of the endothelial layer promotes 
accumulation of low-density lipoprotein (LDL) particles in the extracellular 
matrix where they become targets for oxidative modifications. The oxLDL 
enhances leukocyte attachment to the endothelial layer and stimulates trans-
migration of leukocytes into the intima. Macrophages express scavenger 
receptors for modified lipoproteins, ingest LDL particles and become foam cells 
(Moore and Freeman 2006). Accumulation of foam cells leads to formation of 
the lipid core. T-lymphocytes produce γ-interferon and lymphotoxin, which 
stimulate macrophages and endothelial cells. Moreover, activated leukocytes 
secrete fibrogenic mediators, which promote migration and proliferation of 
VSMC (Libby et al. 2002). Proliferating VSMC produce extracellular matrix 
proteins, which form fibrous caps found on atherosclerotic plaques. Inflamma-
tion does not only promote formation of atheroma but it also contributes to 
acute thrombotic complications of atherosclerosis (Cimmino et al. 2011). 
Activated macrophages produce proteolytic enzymes, which stimulate plaque 
destabilization and rupture (Peeters et al. 2011). In addition, macrophages 
release tissue factor that, upon plaque rupture, contributes to thrombus for-
mation (Badimon et al. 2011). 
Recognition of the central role of inflammation in atherogenesis has stimu-
lated the evaluation of different inflammatory markers as potential predictors of 
CV risk. Increased circulating levels of cytokines, chemokines, cell-adhesion 
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molecules and high-sensitivity C-reactive protein (hsCRP) have been shown to 
be involved in the pathogenesis of atherosclerosis (Szmitko et al. 2003; Ridker 
et al. 2005) and they also predict adverse CV events (Blankenberg et al. 2001; 
Danesh et al. 2004). 
 
 
2.3.1. Soluble intercellular adhesion molecule-1 
Structurally, sICAM belongs to the immunoglobulin superfamily. The sICAM 
promotes adhesion of monocytes to the endothelium and facilitates their migra-
tion into subendothelial space (Witkowska and Borawska 2004). Consistent 
with these data, sICAM is related to endothelial dysfunction in apparently 
healthy subjects (Kals et al. 2008). Moreover, sICAM is an established marker 
of CV disease (Witowska and Borawska 2004). Previous studies have shown 
that circulating sICAM levels are elevated in patients with hypertension (Rohde 
et al. 1999), unstable angina pectoris (Ghaisas et al. 1997), carotid artery 
atherosclerosis (Gross et al. 2012) and diabetes mellitus (Heilman et al. 2009b). 
It has been demonstrated that sICAM predicts development of PAD in middle-
aged men (Pradhan et al. 2002) and correlates with treadmill walking distance 
in patients with intermittent claudication (Nylaende et al. 2006).  
 
 
2.3.2. Interleukin-6 and C-reactive protein  
Interleukin-6 (IL-6) is a multifunctional pro-inflammatory cytokine with a 
variety of biological activities, including the ability to stimulate differentiation 
of B- and T-cells as well as activate macrophages (Kanda and Takahashi 2004). 
Elevated IL-6 levels have been associated with increased CV risk among 
apparently healthy men (Ridker et al. 2000). Moreover, IL-6 is an important 
stimulus to the production of acute phase proteins, such as CRP (Yudkin et al. 
2000). Elevated CRP has been widely accepted as a potent indicator of CV risk. 
It has been shown that elevated CRP has a clear prognostic value for major CV 
events and mortality (Ridker et al. 1997), whereas lowering of CRP is 
associated with a reduction of CV risk (Ridker et al. 2009). Besides its role as a 
„bystander”, CRP has been shown to exert a wide array of pro-atherogenic 
effects, including impairment of endothelial function (Venugopal et al. 2002), 
stimulation of plaque remodelling (Montero et al. 2006) and activation of 
coagulation (Cermak et al. 1993). 
 
  
2.3.3. β2-microglobulin 
The β2M is a nonglycosylated protein that is synthesized by all nucleated cells 
and it forms a light chain subunit of the major histocompatibility complex 
(MHC) class I antigen (Saijo et al. 2005). Because it is noncovalently asso-
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ciated with the α-chain of MHC class I molecules and has no direct attachment 
to cell membrane, β2M can exchange with free soluble β2M on cell surface (Shi 
et al. 2009). Serum β2M level is associated with carotid artery intima-media 
thickness (IMT) (Zumrutdal et al. 2005) and independently predicts total 
mortality in a general population of older adults (Shinkai et al. 2008). As the 
surfaces of lymphocytes and monocytes are rich in β2M and as it is associated 
with autoimmune and infectious diseases (Shi et al. 2009), β2M might be 
implicated in the regulation of inflammatory response (Xie and Yi 2003). 
 
 
2.3.4. Inflammation and arterial stiffness 
The association between inflammation and arterial stiffness is well recognized. 
It has been shown that aPWV (Yasmin et al. 2004) and AIx (Kampus et al. 
2004) are positively associated with CRP in apparently healthy individuals and 
in patients with acute ischaemic stroke (Tuttolomondo et al. 2010). Similarly, 
aPWV is related to serum IL-6 in general population (Schnabel et al. 2008). In 
addition, increased baPWV is related to the combination of high β2M and high 
CRP in clinically healthy subjects (Saijo et al. 2005). However, there are 
limited data exist on associations between inflammatory markers and aortic 
stiffness in patients with PAD. In the present thesis, we investigated the 
possible relationship of aPWV with CRP (Paper I), β2M (Paper II), IL-6 (Paper 
III) and sICAM (Paper III) in PAD patients and in apparently healthy subjects. 
 
  
2.4. Oxidative stress 
A net of pro-oxidants and the antioxidant defence system are normally balanced 
in the body (Zilmer et al. 2010). Principal pro-oxidants are reactive species 
(including free radicals). Reactive species, which are divided into reactive 
oxygen species (ROS) and reactive nitrogen species, mediate the main effects of 
other pro-oxidative factors (Sies 1991; Halliwell 1999). In the human body, the 
most important ROS include superoxide radical, hydroxyl radical, lipid peroxyl 
radical and non-radical hydrogen peroxide (the latter is produced from 
superoxide by superoxide dismutase). The principal reactive nitrogen species 
are NO radical and non-radical peroxynitrite (Zilmer et al. 2010). Most of the 
mentioned reactive species originate from endogenous sources as by-products 
of normal essential metabolic processes, while exogenous sources involve expo-
sure to cigarette smoke, environmental pollutants, radiation, drugs, bacterial 
infections, excess of food iron and dysbalanced intestinal microflora (Zilmer et 
al. 2010). Thus, abnormal formation of reactive species can occur in vivo and it 
leads to the damage of lipids, proteins, nucleic acids and carbohydrates in cells 
and tissues. Excessive production of reactive species causes an imbalance in the 
system of pro- and antioxidants. Any imbalance in favour of pro-oxidants can 
potentially lead to damage, which is termed as OxS (Tsutsui et al. 2011). 
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Recently, an additional adapted concept of OxS has been advanced. According 
to the novel concept, OxS is defined as „a disruption of redox signalling and 
control” (Jones and Go 2010), emphasizing the impact of the redox ratio as a 
good tool for quantification of OxS. The physiological grade of OxS is needed 
for numerous biofunctions, such as intracellular messaging, growth, cellular 
differentiation, phagocytosis and immune response (Elahi et al. 2009). How-
ever, prolonged high-grade OxS is one of the key players in the pathogenesis of 
CV diseases (Drummond et al. 2011). 
  
 
2.4.1. Oxidized low-density lipoprotein 
Oxidative modification of LDL is a key step in initiation and progression of 
atherosclerosis (Stocker and Keaney 2004; Huang et al. 2011). Previous in vitro 
studies have shown that macrophages (Parthasarathy et al. 1986) and lympho-
cytes (Lamb et al. 1992) are capable of oxidizing LDL. The oxLDL leads to 
endothelial dysfunction, which is the initial step in the formation of an atheroma 
(Ahmadi et al. 2010; Zilmer et al. 2010). In addition, oxLDL promotes the 
growth and migration of VSMC, monocytes and fibroblasts (Holvoet and 
Collen 1994). Moreover, previous studies have suggested that oxLDL may also 
play a role in triggering thrombosis by inducing platelet adhesion and by 
decreasing the fibrinolytic capacities of endothelial cells (Holvoet and Collen 
1994; Matsuura et al. 2003).  
Recent research suggests that increased oxLDL levels might have a 
destabilizing effect on plaque composition by enhancing the inflammatory 
processes and surface thrombosis (Ehara et al. 2001). It has been demonstrated 
that the surface area containing oxLDL-positive macrophages is significantly 
higher in patients with unstable angina than in those with stable angina (Ehara 
et al. 2001). Furthermore, oxLDL levels are independently related to IMT 
(Kampus et al. 2007) and plaque size (Andersson et al. 2009) in the carotid 
artery. In addition, oxLDL levels are significantly associated with presence and 
extent of carotid atherosclerosis (Tsimikas et al. 2006) and predict CV events in 
clinically healthy subjects (Lobbes et al. 2006). 
Previous studies suggest that oxLDL could contribute to VCa. It has been 
shown that oxLDL stimulates VCa (Tang et al. 2006), whereas inhibition of 
oxLDL production attenuates VCa (Tang et al. 2007) in rats. The results of in 
vitro studies indicate that oxLDL decreases the gene expression of OPG (Liu et 
al. 2011) and increases the activity of alkaline phosphatase (Lomashvili et al. 
2004). However, no studies have assessed possible association between the 
serum levels of OPG and oxLDL in patients with atherosclerosis. In Paper I, we 
investigated the potential relationship between OPG and oxLDL levels in 
patients with PAD and in healthy subjects. 
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2.4.2. Oxidative stress and arterial stiffness 
The oxLDL may be implicated in arterial stiffening. Recent research indicates 
that serum oxLDL is associated with baPWV in newly-diagnosed diabetes 
patients (Ha et al. 2011). Furthermore, the results of a large cross-sectional 
study show that oxLDL levels are independently associated with aPWV in 
community-dwelling older adults (Brinkley et al. 2009). However, only limited 
data are available regarding the relationship between serum oxLDL and aortic 
stiffness in subjects with clinically evident PAD. In Paper IV, we investigated 
the possible association between aPWV and serum oxLDL in PAD patients and 
in apparently healthy subjects. 
 
 
2.5. Patients with peripheral arterial disease 
Lower-extremity PAD is a manifestation of systemic atherosclerosis, which 
predominantly affects the distal aorta and the lower-extremity arteries (Hirsch et 
al. 2006). The PAD affects about 5% of the population aged over 55 years, in 
the Western world (Fowkes et al. 1991). The prevalence of PAD is age-
dependent, reaching 10% in people aged over 60 years (Criqui 2001) and 20% 
in those aged over 75 (Selvin and Erlinger 2004).  
 
 
2.5.1. Assessment of severity of peripheral arterial disease 
The main symptoms of PAD include intermittent claudication, ischaemic rest 
pain, ulceration and gangrene (Beard 2000). However, PAD is often under-
diagnosed, which may be partly due to the fact that only 10–30% of all PAD 
patients present with classic clinical symptoms (Hirsch et al. 2007). Coexisting 
musculoskeletal disease or neuropathy may confound the clinical picture, and 
almost half of patients are so sedentary as to be asymptomatic (McDermott et 
al. 2004). Nonetheless, PAD patients are still at a significant risk of developing 
serious CV complications, such as myocardial infarction and stroke (Criqui et 
al. 1997; Selvin and Erlinger 2004). Therefore, early diagnosis of PAD would 
trigger intensive risk factor modification and therapy. 
Several tests and imaging techniques have been designed for the detection of 
PAD in clinical practice. The ABPI is a noninvasive test of choice when eva-
luating a patient for PAD (Hirsch et al. 2006). Previous research demonstrates 
that with an ABPI diagnostic threshold of 0.9, the sensitivity of the ABPI was 
95% and the specificity was 100% for detection of haemodynamically signi-
ficant stenoses (Fowkes 1988). Duplex sonography is a noninvasive test to 
determine the location of PAD and to delineate stenotic versus occlusive lesions 
(Moneta et al. 1992). For detection of haemodynamically significant stenoses, 
the sensitivity of the duplex sonography was 88% and the specificity was 96% 
(Collins et al. 2007). Digital subtraction angiography (DSA) is a well-estab-
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lished technique for evaluating severity, location and extent of PAD (Norgren et 
al. 2007) and allows endovascular treatment of haemodynamically significant 
arterial stenoses or occlusions. However, in many centres, magnetic resonance 
angiography (MRA) and computed tomography angiography (CTA) are widely 
used for the initial diagnostic evaluation and treatment planning of patients with 
PAD. For detection of haemodynamically significant stenoses in the lower-
extremity arteries, MRA had the sensitivity and the specificity of 95% and 97%, 
respectively, whereas both the sensitivity and the specificity of CTA were 91% 
(Collins et al. 2007). 
 
Measurement of ABPI is widely used for screening and estimation of progres-
sion rate of PAD. The ABPI represents a ratio of ankle systolic BP to brachial 
systolic BP. The ABPI less than 0.9 is considered suggestive of PAD (Hirsch et 
al. 2006). Decreased ABPI is related to presence of CV risk factors, subclinical 
CV disease or development of CV events (Newman et al. 1993; Leng et al. 
1996; Heald et al. 2006). Recent meta-analysis has shown that subjects with 
low ABPI but without prior history of CAD have increased all-cause mortality 
and a trend for increased CV mortality (Fowkes et al. 2008). However, ABPI 
greater than 1.4 might indicate poor compressibility of the lower-extremity 
arteries (usually in patients with diabetes) and is related to presence of medial 
artery calcification (Kennedy et al. 2005). Accordingly, ABPI greater than 1.4 
is associated with a higher risk of CV mortality as compared to normal ABPI 
(Resnick et al. 2004). 
The relationship between ABPI and arterial stiffness remains controversial. 
In non-diabetic PAD patients, baPWV and brachial-knee pulse wave velocity 
(bkPWV) are positively associated with ABPI (Khandapour et al. 2009). In 
contrast, stiffness of the carotid artery is inversely related to ABPI in elderly 
subjects (Lind 2011). Moreover, recent research indicates that ABPI is not 
associated with aPWV in the clinically healthy subjects (Rabkin et al. 2012). 
However, there are no data about the association between ABPI and aPWV in 
the patients with PAD. In Paper IV of the present thesis, we assessed the 
possible relationship between aPWV and ABPI in the PAD patients and in 
apparently healthy subjects. 
 
2.5.1.2. Angiographic score  
The semiquantitative method for assessment of lower-extremity atherosclerosis 
from routine angiographic images was introduced by Bollinger in 1981 
(Bollinger et al. 1981). The Bollinger scoring system assigns different scores to 
plaques, stenoses and occlusions. The scores for each of the arterial segments 
are then added up to obtain AngSc for each patient. Thus, evaluation of AngSc 
provides information about the site and severity of atherosclerotic lesions in 
2.5.1.1. Ankle-brachial pressure index 
31 
patients with PAD (Nylaende et al. 2006). Several studies have demonstrated 
that AngSc is inversely related to ABPI (Delius and Erikson 1969; Kiekara and 
Riekkinen 1985; Muller-Buhl et al. 1999) and it is an independent risk factor 
for major amputation in diabetic subjects (Faglia et al. 1998). Moreover, AngSc 
is negatively correlated with maximum treadmill walking distance (Nylaende et 
al. 2006) and positively correlated with duration of claudication (Muller-Buhl et 
al. 1999). However, there are no data regarding the possible association 
between aortic stiffness and severity grade of PAD as assessed by DSA. In 
Paper IV we investigated the relationship between aPWV and AngSc in patients 
with symptomatic PAD. 
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3. AIMS OF THE STUDY 
Overall aim 
To measure aortic stiffness (functional profiling), aortic calcification (structural 
profiling), angiographic score (structural profiling), and to assess levels of 
biomarkers of calcification, inflammation and oxidative stress (biochemical 
profiling) in patients with peripheral arterial disease and in clinically healthy 
subjects. To evaluate the relationships between functional, biochemical and 
structural profiles of the arterial damage and to estimate their potential roles in 
determining arterial dysfunction in atherosclerosis. 
 
 
Specific aims 
1. To evaluate aortic pulse wave velocity (functional profiling) and serum 
levels of osteoprotegerin and oxidized low-density lipoprotein (biochemical 
profiling) and to assess their relationship in patients with symptomatic 
peripheral arterial disease in comparison with clinically healthy individuals.  
2. To measure aortic pulse wave velocity (functional profiling), plasma  
β2-microglobulin and fetuin-A levels (biochemical profiling) in patients with 
symptomatic peripheral arterial disease and in clinically healthy subjects and 
to test if elevated plasma β2-microglobulin is associated with increased aortic 
stiffness and plasma fetuin-A levels. 
3. To assess aortic calcification score (structural profiling), aortic pulse wave 
velocity, ankle-brachial pressure index (functional profiling) and serum 
vitamin D (biochemical profiling) and to evaluate the relationship between 
these parameters in patients with symptomatic peripheral arterial disease as 
well as in clinically healthy subjects.  
4. To measure aortic pulse wave velocity (functional profiling), serum 
osteopontin and oxidized low-density lipoprotein (biochemical profiling) and 
to examine the relationship between the functional and biochemical profiles 
in patients with symptomatic peripheral arterial disease and in clinically 
healthy individuals.  
5. To investigate the relationship of aortic pulse wave velocity (functional 
profiling) with angiographic score (structural profiling) in patients with 
atherosclerosis. 
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4. SUBJECTS AND METHODS 
4.1. Study subjects 
4.1.1. Clinically healthy subjects 
The total number of the participants in the control group was 84. The control 
group consisted of 68 subjects in Paper I, 66 subjects in Paper II, 74 subjects in 
Paper III and 84 subjects in Paper IV (Table 1). All participants were men. 
Clinically healthy subjects were recruited by a family physician and by a 
specialist of sports medicine. The exclusion criteria for the control group were 
the following (based on clinical examination, ECG and blood tests): CAD, 
cardiac arrhythmias or valve pathologies, cerebral atherosclerotic disease, PAD, 
diabetes mellitus (fasting serum glucose level >7 mmol/L), malignancies, renal 
failure (estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2) and 
known inflammatory conditions. The control subjects did not use any 
medications on a regular basis. 
 
 
4.1.2. Patients with peripheral arterial disease 
The study population comprised 79 men with symptomatic PAD. The patients’ 
group consisted of 69 subjects in Paper I, 66 subjects in Paper II, 78 subjects in 
Paper III and 79 subjects in Paper IV (Table 1). The patients were recruited 
from the Department of Vascular Surgery, Tartu University Hospital, Estonia. 
The diagnosis of PAD required (1) clinical symptoms of PAD, (2) ABPI <0.9 
and (3) significant stenoses or occlusions of arteries confirmed by angiography 
(DSA or CT). The patients had stages II–IV of chronic ischaemia as defined by 
Fontaine: stage II = intermittent claudication (n=48, n=48, n=53 and n=54 in 
Papers I–IV, respectively); stage III = leg pain at rest (n=14, n=13, n=17 and 
n=17 in Papers I–IV, respectively); stage IV = focal tissue necrosis or gangrene 
(n=7, n=5, n=8 and n=8 in Papers I–IV, respectively). Patients were excluded in 
case they had had myocardial infarction, coronary revascularization or 
cerebrovascular events during the previous 6 months, earlier revascularization 
procedures at the lower limb, upper limb occlusive arterial disease, atrial fib-
rillation, valve pathologies, known inflammatory conditions, diabetes mellitus, 
malignancies and renal failure (eGFR <60 ml/min/1.73 m2). Overall, 21 (30.4%) 
patients with hypertension and 7 (10.1%) patients with CAD were included in 
Paper I; 21 (31.8 %) patients with hypertension and 7 (10.6%) patients with 
CAD were included in Paper II; 30 (38.5%) patients with hypertension and 12 
(15.4%) patients with CAD were included in Paper III; 31 (39%) patients with 
hypertension and 12 (15%) patients with CAD were included in Paper IV. 
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4.2. Study design  
The subjects were studied in the morning between 8 and 10 AM. They had 
abstained from smoking and intake of caffeine-containing food and beverages 
for the previous 12 hours. Studies were conducted in a quiet temperature-
controlled room. First, height and weight were assessed and, next, body mass 
index (BMI) was calculated. After the subjects had spent 15 minutes resting in 
the supine position, brachial BP and radial artery waveforms were recorded. 
Further, aPWV, bPWV, augmentation index corrected for a heart rate of 75 
beats per minute (AIx@75) and ABPI were measured (Table 1). All measure-
ments were made in duplicate at each time point and the average of the two 
measurements was used in the analysis. Twenty millilitres of blood were drawn 
from the antecubital fossa into plain tubes. The subjects then underwent CT 
(Paper III). The next day, the patients underwent routine DSA of the aorta and 
the arteries of the lower extremities (Paper IV). 
The study complies with the Declaration of Helsinki. The study protocol was 
approved by the Ethics Committee of the University of Tartu. All subjects gave 
their written informed consent. 
 
Table 1. Study participants and vascular parameters. 
Paper 
Study participants Vascular parameters 
Patients Controls aPWV bPWV AIx@75 ABPI ACS AngSc 
Number Age Number Age       
I 69 63±7 68 54±8 + + + + – – 
II 66 63±7 66 55±6 + + + + – – 
III 78 63±7 74 61±10 + + + + + – 
IV 79 64±7 84 63±8 + + + + – + 
 
 
4.3. Methods 
4.3.1. Measurement of biomarkers 
Plasma glucose as well as serum LDL, high-density lipoprotein (HDL), tri-
glycerides and creatinine were measured according to standardized protocols in 
the local clinical laboratory. Serum lipid levels were measured by the enzymatic 
colorimetric method on the Hitachi 912 analyser (Roche Diagnostics®, Basel, 
Switzerland). Plasma glucose was assessed by the hexose kinase method on a 
Hitachi 912 analyser (Roche Diagnostics®, Basel, Switzerland). Kinetic colori-
metric method was used for determination of serum creatinine. Measurements 
were made using the Hitachi 912 analyser (Roche Diagnostics®, Basel, 
Switzerland). Calculation of eGFR was performed using the Modification of 
Diet in Renal Disease formula, equation MDRD 1 (Brosius et al. 2006). 
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4.3.1.1. Biomarkers of calcification 
Biomarkers of calcification (OPG, OPN, fetuin-A and 25(OH)D) were 
measured from serum, which was collected and stored at –70ºC until analysis. 
 
4.3.1.1.1. Serum level of osteoprotegerin 
Serum OPG was measured by an enzyme-linked immunosorbent assay using a 
commercially available kit (Human Osteoprotegerin ELISA; Biovendor, 
Heidelberg, Germany) (Paper I). Samples were incubated in microplate wells 
pre-coated with monoclonal anti-human OPG antibody. After incubation and 
washing, biotin labelled polyclonal anti-human OPG antibody was added and 
incubated with captured OPG. After another washing, Streptavidin-horseradish 
peroxidase conjugate was added. After incubation and washing, a substrate 
solution was added. The reaction was stopped by addition of an acidic solution 
and the absorbance of the resulting yellow product was proportional to the 
concentration of OPG. The intra- and inter-assay coefficients of variation for 
OPG were 3.5% and 5.8%, respectively. 
 
4.3.1.1.2. Serum level of osteopontin 
Serum OPN levels were measured using an enzyme-linked immunosorbent 
assay (R&D Systems, Minneapolis, Minnesota, USA) (Paper IV). A mono-
clonal antibody specific for OPN was pre-coated onto a microplate. Then the 
standards and the samples were pipetted into the wells and any OPN present 
was bound by the immobilized antibody. After incubation and washing, an 
enzyme-linked polyclonal antibody specific for OPN was added to the wells. 
After another washing, a substrate solution was added to the wells and colour 
developed in proportion to the amount of OPG bound in the initial step. Colour 
development was stopped and the intensity of the colour was measured. The 
intra- and inter-assay coefficients of variation for OPN were 4.0% and 6.6%, 
respectively.  
 
4.3.1.1.3. Serum level of fetuin-A 
Fetuin-A was measured by an enzyme-linked immunoabsorbent assay using a 
commercially available kit (BioVendor Laboratory Medicine, Inc.® Brno, Czech 
Republic) (Paper II). Samples were incubated in microplate wells pre-coated 
with polyclonal antibody specific for fetuin-A. After incubation and washing, 
polyclonal anti-human fetuin-A antibody, conjugated with horseradish peroxi-
dase, was added to the wells and incubated with captured fetuin-A. The reaction 
was stopped by addition of an acidic solution and the absorbance of the resul-
ting yellow product was measured. The absorbance was proportional to the 
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concentration of fetuin-A. The intra- and inter-assay coefficients of variation for 
fetuin-A were 3.9% and 5.4%, respectively. 
 
4.3.1.1.4. Serum level of 25-hydroxyvitamin D 
Serum 25(OH)D level was measured using a radioimmune assay (25-Hydro-
xyvitamin D, 125I Ria Kit, DiaSorin Corporation, Minnesota, USA) (Paper III). 
The assay consisted of two steps. The first step involved an extraction of 
25(OH)D from serum with acetonitrile. The extraction was followed by 
competitive radioimmune assay using 125I-labelled 25(OH)D and antibody to 
25(OH)D. The sample, antibody and tracer were incubated for 90 minutes. 
Phase separation was accomplished after 20-minute incubation with a second 
antibody precipitating complex. Then a buffer was added to reduce non-specific 
binding. This was followed by centrifugation. Intra- and inter-assay coefficients 
of variation were 8.1% and 10.2%, respectively. 
 
4.3.1.2. Biomarkers of inflammation 
The biomarkers of inflammation (sICAM, IL-6, hsCRP and β2M) were determi-
ned from serum or plasma, which was collected and kept frozen at –70ºC until 
analysis. 
 
4.3.1.2.1. Plasma level of soluble intercellular adhesion molecule-1 
The plasma level of sICAM was measured by an enzyme-linked immuno-
sorbent assay using a commercially available kit (Human soluble intercellular 
adhesion molecule-1 Immunoassay; R&D Systems; Minneapolis, USA) (Papers 
I and III). This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody, specific for sICAM, was pre-coated onto a 
microplate. Standards, samples, controls and the conjugate were pipetted into 
wells and any sICAM present was sandwiched by the immobilized antibody and 
the enzyme-linked monoclonal antibody specific for sICAM. Following a wash 
to remove the unbound substances or the antibody-enzyme reagent, a substrate 
solution was added and colour developed in proportion to the amount of bound 
sICAM. Colour development was stopped and the intensity of colour was 
measured at 450 nm, with the correction wavelength set at 620 nm, by a photo-
meter Sunrise (Tecan Austria GmbH®, Salzburg, Austria). The intra- and inter-
assay coefficients of variation for sICAM were 4.8% and 7.4%, respectively. 
 
4.3.1.2.2. Serum level of interleukin-6 
Serum levels of IL-6 were determined using a chemiluminescent immunoassay 
(Immulite; Diagnostic Products Corporation, Los Angeles, USA) (Paper III). 
This assay employed the quantitative sandwich enzyme immunoassay technique. 
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A monoclonal antibody specific for IL-6 was pre-coated onto a microplate. 
Standards and samples were pipetted into the wells, and any IL-6 present was 
bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for IL-6 was added 
to the wells. Following a wash to remove unbound antibody-enzyme reagent, an 
enhanced luminol/peroxide substrate solution was added to the wells and light 
was produced in proportion to the amount of IL-6 bound in the initial step. A 
microplate luminometer was used to measure the intensity of emitted light. The 
minimum detectable value of the IL-6 assay was 2 pg/mL.  
 
4.3.1.2.3. Plasma level of C-reactive protein 
The plasma level of CRP was measured by a validated latex particle-enchanced 
high-sensitivity immunoturbidimetric assay (CRP (Latex) HS, Roche Diagostics 
Gmbh®, Mannheim, Germany), and analysed by the Hitachi 912 analyser 
(Roche Diagostics®, Basel, Switzerland) (Papers I–IV). Latex particles coated 
with an antibody specific for human CRP aggregated in the presence of CRP 
from the sample forming immune complexes. The immune complexes caused 
an increase in light scattering which was proportional to the concentration of 
CRP in the serum. Light scattering was measured by reading turbidity at 570 
nm. The CRP concentration curve was determined from a calibration curve 
developed from CRP standards of known concentration. The intra- and inter-
assay coefficients of variation for CRP were 1.8% and 2.9%, respectively. 
 
4.3.1.2.4. Plasma level of β2-microglobulin 
Plasma β2M concentration was measured by a chemiluminescent immunoassay 
using a commercially available kit (L2KBM2, Siemens Medical Solutions 
Diagnostics®, California, USA) in the IMMULITE 2000 automated analyser 
(Siemens Medical Solutions Diagnostics®, California, USA) (Paper II). This 
assay employed the quantitative sandwich enzyme immunoassay technique. The 
first monoclonal antibody was coated on the surface of the microtiter wells and 
the second monoclonal antibody was used as the tracer. The β2M molecules 
present in the standard solution or serum were bound to both antibodies. Follo-
wing the formation of the coated antibody-antigen-antibody-enzyme complex, 
the unbound antibody-enzyme labels were removed by washing. The horse-
radish peroxidase activity bound in the wells was then assayed by adding the 
substrate reagents and by producing chemiluminescent reactions. The intensity 
of the light emitted from the associated well was proportional to the amount of 
the enzyme present and was directly related to the amount of β2M in the sample. 
By reference to a series of β2M standards assayed in the same way, the 
concentration of β2M in the unknown sample was quantified. The intra- and 
inter-assay coefficients of variation for β2M were 4.2% and 11%, respectively. 
10
38 
4.3.1.3. Plasma level of oxidized low-density lipoprotein 
Serum oxLDL levels were determined by an enzyme-linked immunosorbent 
assay (Mercodia AB, Uppsala, Sweden) (Papers I and IV). This is a solid phase 
two-site enzyme immunoassay, based on the direct sandwich technique in 
which two monoclonal antibodies are directed against separate antigenic 
determinants on the oxidized apolipoprotein B molecule. During incubation and 
a simple washing step that removed non-reactive plasma components, a peroxi-
dase conjugated anti-apoprotein B antibody recognized oxLDL bound to the 
solid phase. After a second incubation and a simple washing step that removed 
the unbound enzyme-labelled antibody, the bound conjugate was detected with 
3,3’,5,5’-tetramethylbenzidine. The reaction was stopped by adding an acid to 
obtain a colorimetric endpoint that was read spectrophotometrically at 450 nm 
by a photometer Sunrise (Tecan Austria GmbH®, Salzburg, Austria). The intra- 
and inter-assay coefficients of variation for oxLDL were 5.5% and 6.2%, 
respectively. 
 
 
4.3.2. Measurement of blood pressure 
The BP was measured in the supine position from the left arm with an auto-
mated digital oscillometric BP monitor (OMRON M4-I; Omron Healthcare 
Europe, Hoofdorp, the Netherlands). The MAP was obtained by integration of 
the radial pressure waveform using the Sphygmocor software (SCOR® Px, 7.0; 
AtCor Medical, Sydney, Australia). The PPP was calculated as the difference 
between PSBP and peripheral diastolic blood pressure (PDBP). All measure-
ments of BP were made in duplicate and the mean values were used in subse-
quent analysis. 
 
 
4.3.3. Assessment of arterial stiffness 
4.3.3.1. Pulse wave velocity 
The PWV was measured by the foot-to-foot method, using the Sphygmocor 
device. The aPWV was determined by sequentially recording ECG-gated caro-
tid and femoral artery waveforms using the SphygmoCor software (DeLoach 
and Townsend 2008). Wave transit time was calculated as the time delay 
between the arrival of the pulse wave at the common carotid artery and the 
common femoral artery using the R wave of a simultaneously recorded ECG as 
the reference frame. The surface distance between the two recording sites was 
measured as the distance from the suprasternal notch to the common femoral 
artery minus the distance from the suprasternal notch to the common carotid 
artery (DeLoach and Townsend 2008). The within- and between-observer 
coefficients of variation for aPWV were 2.3% and 6.2%, respectively. The 
bPWV was measured from the carotid and radial waveforms. The surface 
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distance between the recording sites was estimated as the distance from the 
suprasternal notch to the radial artery minus the distance from the suprasternal 
notch to the carotid artery (Wilkinson et al. 1998). The within- and between-
observer coefficients of variation for bPWV were 2.9% and 5.5%, respectively. 
All measurements were made in duplicate by two trained investigators, and 
mean values were used in subsequent analysis.  
 
4.3.3.2. Pulse wave analysis 
Radial artery pressure waveforms were obtained with a high-fidelity appla-
nation tonometer (SPT-301B; Millar Instruments, Houston, Texas, USA) from 
the wrist of the left hand. After 20 sequential waveforms had been acquired, the 
integral software (SCOR Px, 7.0; AtCor Medical, Sydney, Australia) was used 
to generate a corresponding central (ascending aortic) waveform using a gene-
ralized transfer function, which has been prospectively validated for assessment 
of central BP (Sharman et al. 2006). The AIx, travel time of the reflected wave 
(Tr), CSBP, central diastolic blood pressure (CDBP) and CPP were determined 
by PWA. The AIx was calculated as the difference between the second and the 
first systolic peaks, divided by CPP and expressed in percentages (Wilkinson et 
al. 1998). The AIx values were adjusted to a heart rate of 75 beats/min using a 
SphygmoCor built-in algorithm. The within- and between-observer coefficients 
of variation for AIx@75 were 3.4% and 7.1%, respectively. 
 
 
4.3.4. Measurement of ankle-brachial pressure index 
The ABPI was measured using the Bidirectional Doppler MD 6 (D.E, Hokan-
son, Bellevue, Washington, USA). Systolic BP was assessed bilaterally over the 
brachial, tibialis posterior and dorsalis pedis arteries. The higher systolic BP of 
the dorsalis pedis or the posterior tibial artery was used for calculation of the 
ABPI (Hirsch et al. 2006). Two readings of the ABPI were obtained and the 
mean was calculated. The lower ABPI of the two legs was included in statistical 
analysis. The within- and between observer coefficients of variation for ABPI 
were 4.1% and 8.6%, respectively. 
 
 
4.3.5. Measurement of calcification score 
The CT scans of the aorta were performed in 52 patients with PAD and in 60 
clinically healthy subjects. All study participants were informed about the pur-
pose, methods, radiation dose and risks associated with radiation exposure. We 
could not perform CT scans in all of the subjects due to the lack of consent and 
considering also the fact that some patients had several CT scans in their 
medical history. The entire aorta (from the aortic valve to bifurcation) was 
visualized by obtaining 5 mm thick slices through the thorax, abdomen, and 
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pelvis using non-contrast helical CT (GE LightSpeed 16, General Electrical 
Medical Systems, Milwaukee, Wisconsin, USA; total dose: <8 mSv). Analysis 
was conducted using a Siemens Syngo Multimodality Workplace workstation. 
Aortic calcification score (ACS) was measured by an independent observer. The 
degree of calcification was determined by the volume scoring method. The 
number of voxels of 130 or greater Hounsfield units within the wall of the aorta 
yielded a calcification score in cubic centimetres. This is a validated and 
accurate technique that compares favourably with electron beam CT (Hopper et 
al. 2002).  
 
 
4.3.6. Measurement of angiographic score 
All patients were examined with DSA (Axiom Artis, Siemens Medical Solu-
tions, Forchheim, Germany) of the aorta and the arteries of the lower extre-
mities using the standard technique via the femoral approach at the Department 
of Radiology, Tartu University Hospital, Estonia. In the majority of the PAD 
patients DSA was followed by percutaneous transluminal angioplasty with 
stenting or by bypass surgery. In some patients conservative treatment was 
chosen due to anatomical considerations, concomitant diseases and the high risk 
of surgery. The following arterial segments were evaluated: abdominal aorta, 
common iliac artery, external iliac artery, common femoral artery, profunda 
femoris artery, superficial femoral artery, popliteal artery, tibio-peroneal trunk, 
anterior tibial artery, posterior tibial artery and peroneal artery. Severity of 
stenosis was assessed according to the following validated grading system:  
0 = normal; 1 = stenosis < 50%; 2 = stenosis > 50%; 3 = occlusion (Nylaende et 
al. 2006). Different scores for each of the 21 segments were then added up to 
obtain AngSc for each patient, 63 being the maximal score. The AngSc was 
evaluated independently by an experienced radiologist, who was blinded to the 
results of haemodynamic and laboratory measurements. The within-observer 
coefficient of variation for AngSc was 5.4%. 
 
 
4.3.7. Statistical analysis 
The software R (version 2.8.1 for Windows; The R Foundation for Statistical 
Computing, Vienna, Austria) (Papers I and II) and the software STATISTICA 
(version 10.0 for Windows; StatSoft, Tulsa, Oklahoma, USA) (Papers III and 
IV) were used for all statistical analyses. Continuous variables are shown as a 
mean ± standard deviation or medians with interquartile ranges. Categorical 
variables are presented in percentages. The Kolmogorov-Smirnov test was per-
formed to prove variables for a normal distribution (Papers I–IV). Skewed data 
were log-transformed to obtain a normal distribution and then analysed. As 
there was a significant difference in BP between the study groups, aPWV and 
bPWV were adjusted for MAP before analysis (Papers III and IV). Correlations 
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between continuous variables were quantified using Pearson’s correlation 
coefficient. Multiple regression analysis was performed to investigate the 
independent determinants of aPWV (Papers I, II and IV), OPG (Paper I), β2M 
(Paper II) and ACS (Paper III). Comparisons between the patients and the 
controls were performed using the unpaired t-tests for parametric data and the 
Mann-Whitney U-tests for non-parametrically distributed data. Comparison 
between multiple unpaired groups was performed using the one-way analysis of 
variance (ANOVA) (Paper III). P values of < 0.05 were considered statistically 
significant. 
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5. RESULTS 
5.1. Association between arterial calcification  
and stiffness in patients with symptomatic  
peripheral arterial disease and in healthy subjects 
(Papers I, III and IV) 
 
Association between osteoprotegerin and aortic stiffness (Paper I) 
Characteristics of the study population  
The baseline characteristics of 69 patients and 68 healthy subjects are presented 
in Table 2. The groups did not differ with respect to HDL, eGFR or brachial 
PWV. Our data revealed that OPG level and aPWV were different for the 
patients and for the healthy individuals. There occurred a significant difference 
in median ABPI and hsCRP between the groups. Age, height, BMI, the values 
of peripheral and central BP, heart rate, LDL, triglycerides, oxLDL, sICAM, Tr, 
AIx, AIx@75, prevalence of smoking and use of medications were also 
different for the patients and for the healthy subjects (Table 2).  
 
 
Relationship between arterial stiffness and osteoprotegerin 
Univariate analysis revealed that OPG level correlated significantly with aPWV 
for the patients with PAD (r=0.37, p=0.003) and for the healthy individuals 
(r=0.40, p=0.001) (Figures 4A and 4B, respectively). In multiple regression 
analysis, independent association between aPWV and serum OPG was found 
for the patients and for the healthy subjects (Table 3). In a multiple regression 
model containing only statistically significant variables, OPG, MAP and ABPI 
explained 38% of the variance in aPWV (p<0.0001) for the PAD patients. There 
was no correlation between serum OPG and bPWV in neither of the groups 
(data not shown). 
The OPG level was positively correlated with AIx@75 (r=0.25, p=0.04) and 
negatively with Tr (r=–0.34, p=0.005) for the healthy subjects, but not for the 
patients (data not shown). There did not exist any independent association 
between AIx@75 and OPG level either for the patients or for the healthy 
subjects (data not shown). 
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Table 2. Baseline characteristics of the study subjects (mean ± standard deviation or 
prevalence (%)). 
Variable PAD patients 
(n=69) 
Controls 
(n=68) 
P value 
Age (years) 063.2±7.100 053.9±7.500 <0.01 
BMI (kg/m2) 025.5±3.900 026.9±3.400 0.03 
Height (m) 174.4±6.100 179.2±7.400 <0.01 
PSBP (mmHg) 0148±2000 0128±1500 <0.01 
PDBP (mmHg) 82±10 0077±9000 <0.01 
CSBP (mmHg) 0136±1900 0118±1600 <0.01 
CDBP (mmHg) 0083±1100 0079±1000 0.02 
MAP (mmHg) 0104±1400 0095±1200 0.30 
Heart rate (bpm) 067.2±12.10 058.2±10.20 <0.01 
ABPIa 0.5 (0.2–0.6) 1.1 (1.1–1.2) <0.01 
Total cholesterol (mmol/L) 005.9±1.300 0v5.2±1.000 <0.01 
HDL (mmol/L) 001.3±0.400 001.3±0.300 0.70 
LDL (mmol/L) 004.1±1.100 003.6±0.900 <0.01 
Triglycerides (mmol/L) 001.7±0.700 001.1±0.800 <0.01 
Glucose (mmol/L) 005.6±1.000 005.4±0.500 0.20 
eGFR (ml/min/1.73 m2) 101.8±26.10 098.1±18.00 0.33 
hsCRP (mg/L)a 4.0 (1.4–7.9) 0.9 (0.5–1.4) <0.01 
sICAM (ng/ml) 278.6±73.10 183.5±42.40 <0.01 
OPG (pmol/L) 005.4±1.700 004.4±1.100 <0.01 
oxLDL (U/L) 072.5±27.00 056.0±22.40 <0.01 
AIx (%) 033.1±14.60 021.7±10.70 <0.01 
AIx@75 (%) 028.1±8.100 013.6±11.10 <0.01 
aPWV (m/s) 010.1±2.500 007.6±1.600 <0.01 
bPWV (m/s) 008.9±1.500 008.9±1.200 0.70 
Current smoking, n (%) 69 (100) 2 (2.9) <0.01 
Medication, n (%)    
 Calcium channel blockers 7 (10.1) 0 (0) <0.01 
 ACE inhibitors 7 (10.1) 0 (0) <0.01 
 Angiotensin receptor 
 blockers 
3 (4.3) 0 (0) 0.03 
 Beta-blockers 2 (2.9) 0 (0) 0.16 
 Diuretics 1 (1.4) 0 (0) 0.25 
 Pentoxyfylline  21 (30.0) 0 (0) <0.01 
 Aspirin 10 (14.3) 0 (0) <0.01 
 Statins 2 (2.9) 0 (0) 0.16 
a indicates medians and interquartile ranges. 
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Table 3. Multiple regression model for the patients and for the control subjects with 
aPWV as the dependent variable.  
 Regression 
coefficient Standard error P value 
Patientsa    
 OPG (pmol/L) 0.61 0.20 0.005 
 MAP (mmHg) 0.06 0.02 0.02 
 ABPI –2.10 0.98 0.04 
 eGFR (ml/min/1.73m2) –0.02 0.01 0.10 
 Age (years) 0.05 0.05 0.24 
 Antihypertensive treatment 0.72 0.62 0.25 
Controlsb    
 Age (years) 0.10 0.03 <0.001 
 MAP (mmHg) 0.05 0.01 0.001 
 OPG (pmol/L) 0.33 0.15 0.04 
a R2 value=0.47, p<0.0001, n=69; b R2 value=0.44, p<0.0001, n=68.  
 
 
 
 
Figure 4. Correlation between aPWV and OPG for the PAD patients (Figure 4A, 
r=0.37, p=0.003) and for the healthy individuals (Figure 4B, r=0.40, p=0.001). 
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Association between aortic calcification, vitamin D and aortic stiffness  
(Paper III) 
Participant characteristics 
The characteristics of 78 patients with PAD and of 74 healthy subjects are 
summarized in Table 4. The patients with PAD had higher ACS, aPWV, PSBP, 
PDBP, PPP, CSBP and CPP compared to the controls. In contrast, 25(OH)D 
levels were significantly higher among the healthy subjects. Biomarkers of 
inflammation, such as hsCRP, sICAM and IL-6, were higher in the patient 
group.  
 
 
Relationship between aortic calcification, arterial stiffness and vitamin D 
The log-ACS was significantly correlated with aPWV for the PAD patients 
(r=0.28, p=0.03) and in the controls (r=0.57, p<0.001) (Figure 5). The log-ACS 
showed positive correlation with 25(OH)D levels for the PAD patients (r=0.33, 
p=0.01) and negative correlation for the control subjects (r=–0.47, p<0.001) 
(Figure 6). The log-ACS was positively correlated with log-hsCRP (r=0.29, 
p=0.03) and log-IL-6 (r=0.28, p=0.03) only for the PAD patients. Multivariate 
analysis revealed that log-ACS was independently associated with 25(OH)D, 
age, aPWV, calcium and eGFR for the PAD patients and with 25(OH)D, 
aPWV, cholesterol/HDL ratio and age for the clinically healthy subjects (Table 
5). In a multiple regression model containing only statistically significant 
variables, 25(OH)D, age, aPWV, calcium and eGFR explained 47% of the 
variance in ACS (p<0.001) in the PAD patients. Adjustment for seasonal 
variation of vitamin D, antihypertensive and vasodilator treatment, systolic, 
diastolic and pulse pressure, glucose, LDL, triglycerides, height and weight did 
not alter the associations (data not shown). The log-ACS was significantly 
correlated with AIx@75 (r=0.48, p<0.001) only in the control subjects. 
However, this correlation was not significant after adjustment for confounders.  
Vitamin D correlated significantly with AIx@75 for the controls (r=–0.26, 
p=0.03). There was a trend for emergence of correlation between 25(OH)D 
level and aPWV (r=–0.23, p=0.057) only for the control subjects. 
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Table 4. Baseline characteristics of the study subjects (mean ± standard deviation or 
prevalence (%)). 
Parameter PAD patients (n=78) 
Controls 
(n=74) P value 
Age (years) 0063±7000 61±10 0.1 
BMI (kg/m2) 025.4±3.800 27.0±3.50 <0.01 
ABPI 00.43±0.300 1.2±0.1 <0.01 
ACS (cm3)a 4.9 (2.3–8.9) 0.2 (0.03–1.6) <0.01 
Heart rate (beats/min) 066.6±12.10 58.9±9.20 <0.01 
MAP (mmHg) 103.9±13.80 97.0±11.2 <0.01 
PSBP (mmHg) 148.4±20.8 0 131.9±15.20 <0.01 
PDBP (mmHg) 081.3±10.40 77.9±8.60 0.03 
PPP (mmHg) 066.1±14.60 54.1±10.8 <0.01 
CSBP (mmHg) 135.7±19.20 122.3±16.30 <0.01 
CDBP (mmHg) 082.3±10.90 79.3±9.30 0.07 
CPP (mmHg) 053.4±12.90 43.0±11.2 <0.01 
aPWV (m/s)b 9.8±2.4 8.2±1.6 <0.01 
bPWV (m/s)b 8.7±1.3 8.8±1.2 0.73 
AIx@75 (%) 28.2±8.00 17.1±9.90 <0.01 
Glucose (mmol/L) 5.6±1.0 5.4±0.5 0.13 
Total cholesterol (mmol/L) 5.9±1.2 5.3±1.1 <0.01 
LDL (mmol/L) 4.2±1.1 3.7±1.1 <0.01 
HDL (mmol/L) 1.3±0.4 1.3±0.3 0.49 
Triglycerides (mmol/L) 1.7±0.7 1.1±0.7 <0.01 
eGFR (mL/min/1.73m2) 99.7±25.8 95.1±20.7 0.2 
hsCRP (mg/L)a 4.1 (1.4–8.5) 0.9 (0.5–1.6) <0.01 
Calcium (mmol/L) 2.4±0.2 2.2±0.2 <0.01 
25(OH)D (ng/mL) 15.1±5.40 19.0±5.90 <0.01 
sICAM (ng/mL) 265.5±65.50 174.9±36.30 <0.01 
IL-6 (ng/L)a 4.0 (2.1–7.0) 2.0 (1.9–3.0) <0.01 
Current smoking, n (%) 78 (100) 18 (24) <0.01 
Framingham risk score (%)c  ND 11.4±7.30         ND 
Medication, n (%)    
 Calcium channel blockers 14 (17.9%) 0 (0) <0.01 
 ACE inhibitors 15 (19.2%) 0 (0) <0.01 
 Angiotensin receptor blockers 7 (9%) 0 (0) <0.01 
 Beta-blockers 5 (6.4%) 0 (0) <0.01 
 Diuretics 3 (3.8%) 0 (0) 0.03 
 Pentoxyfylline  31 (39.7%) 0 (0) <0.01 
 Aspirin 20 (25.6%) 0 (0) <0.01 
 Statins 9 (11.5%) 0 (0) <0.01 
a indicates medians and interquartile ranges; b aPWV and bPWV have been adjusted for MAP; 
c risk was not assessed for the PAD patients since they had established vascular disease, which 
indicates high CV risk. 
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Table 5. Multiple regression analysis for the PAD patients and for the control subjects 
with the logarithm of ACS as the dependent variable.  
 Regression 
coefficient Standard error P value 
Patientsa    
 25(OH)D (ng/mL) 0.04 0.01  0.008 
 Age (years) 0.04 0.01 0.01 
 aPWV (m/s)c 0.09 0.04 0.02 
 Calcium (mmol/L) 1.23 0.53 0.02 
 eGFR (mL/min/1.73m2) 0.008 0.003 0.03 
 sICAM (ng/mL) 0.002 0.001 0.13 
Controlsb    
 25(OH)D (ng/mL) –0.05 0.02 0.003 
 aPWV (m/s)c 0.19 0.07 0.01 
 Cholesterol/HDL 0.15 0.07 0.03 
 Age (years) 0.02 0.01 0.03 
a R2 value=0.49, p<0.001, n=46; b R2 value=0.55, p<0.001, n=55; c aPWV has been adjusted for 
MAP. 
 
 
 
Figure 5. Correlation between aPWV and log-ACS for the patients (r=0.28, p=0.03) 
and for the control subjects (r=0.57, p<0.001). The aPWV has been adjusted for MAP. 
Filled dots represent patients; empty dots represent controls. Continuous line represents 
the regression line through the patient data; interrupted line represents the regression 
line through the control data. 
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Figure 6. Correlation between 25(OH)D and log-ACS for the patients (r=0.33, p=0.01) 
and for the control subjects (r=–0.47, p<0.001). Filled dots represent the patients; empty 
dots represent the controls. Continuous line represents the regression line through the 
patient data; interrupted line represents the regression line through the control data. 
 
Association between osteopontin and aortic stiffness (Paper IV) 
Characteristics of the study subjects 
The baseline characteristics of the study subjects are shown in Table 6. The 
groups did not differ with respect to age or BMI. The patients with PAD had 
higher aPWV, AIx@75, heart rate as well as measures of peripheral and central 
BP. In contrast, ABPI was significantly higher among the controls. Biomarkers 
of inflammation and oxidative stress, such as hsCRP, OPN and oxLDL, were 
higher in the patient group. 
 
Relationship between osteopontin and aortic stiffness 
The aPWV correlated significantly with log-OPN (Figure 7) for the patients 
with PAD and for the controls. In multiple regression analysis, aPWV was inde-
pendently associated with AngSc, log-OPN, log-oxLDL and eGFR for the 
patients and with age, log-oxLDL, heart rate, and log-OPN in the controls 
(Table 7). In a multiple regression model containing only statistically significant 
variables, age, log-oxLDL, log-OPN and heart rate explained 37% of the 
variance in aPWV (p<0.001) in the controls. These associations persisted after 
correction for pack-years of smoking, ABPI, BMI, LDL, HDL, triglycerides, 
glucose, heart rate and log-hsCRP.  
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Table 6. Baseline characteristics of the study subjects (mean ± standard deviation or 
prevalence (%)). 
Characteristic PAD patients 
(n=79) 
Controls 
(n=84) 
P value 
Age (years) 64±70 63±80 0.540 
Body mass index (kg/m2) 025.4±3.800 25.6±3.70 0.730 
MAP (mmHg) 103.9±13.80 94.6±9.70 <0.001 
PSBP (mmHg) 148.4±20.80 127.6±10.80 <0.001 
PDBP (mmHg) 081.3±10.40 76.9±8.20 0.003 
PPP (mmHg) 66.1±14.6 50.7±8.80 <0.001 
CSBP (mmHg) 135.7±19.20 117.8±12.60 <0.001 
CDBP (mmHg) 082.3±10.90 78.2±9.10 0.010 
CPP (mmHg) 053.4±12.90 39.5±9.3 <0.001 
Heart rate (beats/min) 066.1±12000 60.0±9.80 <0.001 
AIx@75 (%) 027.9±8.200 018.5±10.90 <0.001 
aPWV (m/s)b 010±2.40 8.4±1.7 <0.001 
bPWV (m/s)b 8.7±1.2 8.9±1.4 0.580 
Angiographic score (AU) 028.3±7.600 ND    ND 
ABPI 00.41±0.280 001.19±0.12000 <0.001 
Glucose (mmol/L) 005.6±10000 5.4±0.5 0.080 
Total cholesterol (mmol/L) 5.9±1.2 5.2±1.1 <0.001 
LDL (mmol/L) 4.2±1.1 3.7±1.1 0.003 
HDL (mmol/L) 1.3±0.4 1.3±0.3 0.700 
Triglycerides (mmol/L) 1.7±0.7 1.2±0.6 <0.001 
hsCRP (mg/L)a 3.9 (1.4–7.6) 0.9 (0.5–1.7) <0.001 
eGFR (ml/min/1.73m2) 099.7±25.80 96.5±1900 0.380 
OPN (ng/mL)a 75 (62.3–85.8) 54.8 (47.7–67.9) <0.001 
oxLDL (U/L)a 67 (52.5–93.5) 47.5 (37–65.5) <0.001 
Current smoking, n (%) 79 (100) 0 <0.001 
Pack-years of smoking  037±160 0 <0.001 
Medication, n (%)    
 Calcium channel 
 blockers 
15 (18.9) 0 (0) <0.001 
 ACE inhibitors 15 (18.9) 0 (0) <0.001 
 Angiotensin receptor 
 blockers 
8 (10.1) 0 (0) <0.001 
 Beta-blockers 6 (7.6) 0 (0) <0.001 
 Diuretics 3 (3.8) 0 (0) 0.200 
 Pentoxyfylline  32 (40.5) 0 (0) <0.001 
 Aspirin 21 (26.6) 0 (0) <0.001 
 Statins 9 (11.4) 0 (0) <0.001 
a indicates medians and interquartile ranges. b aPWV and bPWV have been adjusted for MAP. 
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Table 7. Multiple regression analysis for the PAD patients and for the control subjects 
with aPWV adjusted for MAP as the dependent variable. 
 Regression 
coefficient Standard error P value 
Patientsa    
 Angiographic score (AU) 0.08 0.03 0.01 
 Log-oxLDL 3.71 1.56 0.02 
 Log-OPN 4.36 1.84 0.02 
 eGFR (mL/min/1.73m2) –0.02 0.01 0.02 
 Age (years) 0.07 0.04 0.06 
Controlsb    
 Age (years) 0.07 0.02 0.002 
 Log-oxLDL 2.46 0.98 0.01 
 Log-OPN 3.36 1.4 0.02 
 Heart rate (beats/min) 0.04 0.02 0.02 
 BMI (kg/m2) 0.06 0.04 0.15 
a R2 value=0.44; p<0.001; n=72; b R2 value=0.38; p<0.001; n=83. 
 
 
 
 
Figure 7. Correlation between aPWV and log-OPN for the patients (r=0.39, p<0.001) 
and for the control subjects (r=0.41, p<0.001). The aPWV has been adjusted for MAP. 
Filled dots represent the patients; empty dots represent the controls. Continuous line 
represents the regression line through the patient data; interrupted line represents the 
regression line through the control data. 
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5.2. β2-microglobulin independently predicts aortic 
stiffness in patients with symptomatic peripheral 
arterial disease (Paper II) 
 
Subject characteristics 
The clinical characteristics of 66 patients with PAD and in 66 apparently 
healthy subjects are summarized in Table 8. There was no significant difference 
between the patients and the controls regarding glucose, HDL, GFR or fetuin-A 
levels (Table 8). However, there was a significant difference in age, BMI, 
ABPI, total cholesterol, LDL, triglycerides, hsCRP, β2M, AIx, aPWV and 
smoking status between the groups. Heart rate, MAP, PSBP, PDBP and CSBP 
were also different for the patients and for the controls.  
 
 
Relationship between aortic stiffness and other variables 
Linear regression analysis was used to establish whether aPWV correlated with 
other variables within each group separately. A significant relationship was 
found between aPWV and eGFR or age for the patients (r=–0.34, p=0.005; 
r=0.42, p<0.001, respectively) and for the control group (r=–0.26, p=0.03; 
r=0.53, p<0.001, respectively). There was a significant positive association 
between β2M and aPWV only in the patients (Figure 8). We did not find 
significant correlation between β2M and aPWV in the control group or between 
β2M and AIx for either group (data not shown). To determine whether the 
association between β2M and aPWV was independent of traditional CV risk 
factors or specific factors influencing arterial stiffness, multiple linear reg-
ression models were developed with aPWV as the dependent variable for each 
group separately. The aPWV was independently associated only with β2M and 
age for the patient group (Table 9). In a multiple regression model containing 
only statistically significant variables, β2M and age explained 27% of the 
variance in aPWV (p<0.001) for the PAD patients. In contrast, there did not 
exist any significant association between β2M and aPWV for the controls (data 
not shown). However, aPWV was independently correlated with MAP and age 
for the control subjects (R2=0.41, p<0.001).  
 
 
Relationship between β2-microglobulin and other variables  
Univariate analysis revealed that β2M level was correlated with age both in the 
PAD patients (r=0.48, p<0.001) and in the control subjects (r=0.31, p=0.01). 
Moreover, β2M was inversely correlated with GFR in the patients (r=–0.45, 
p<0.001) and in the controls (r=–0.43, p<0.001). However, plasma β2M was 
significantly correlated with fetuin-A level only for the patient group (Figure 9). 
To determine which biomarkers associated independently with β2M, multiple 
linear regression models were developed for each group with β2M as the 
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dependent variable. The final models indicated that β2M was positively asso-
ciated with fetuin-A, aPWV, age and GFR for the patients group (Table 10), 
while β2M was significantly correlated with age and GFR among the controls 
(R2=0.24, p<0.001). 
 
Table 8. Baseline characteristics of the study subjects (mean ± standard deviation or 
prevalence (%)). 
Characteristic PAD patients 
(n=66) 
Controls 
(n=66) 
P value 
Age (years) 637.20 54.76.30 <0.001 
BMI (kg/m2) 25.540000 26.83.40 0.04 
MAP (mmHg) 1041300 9512 <0.001 
PSBP (mmHg) 1462000 127120 <0.001 
PDBP (mmHg) 81100 7790 0.012 
PPP (mmHg) 66150 5110 <0.001 
CSBP (mmHg) 134190 0 118170 <0.001 
CDBP (mmHg) 82110 7910 0.09 
CPP (mmHg) 53130 3910 <0.001 
Heart rate (beats/min) 67120 5810 <0.001 
ABPI 0.420.300 1.120.14 <0.001 
Total cholesterol (mmol/L) 05.91.290 05.20.98 <0.001 
HDL (mmol/L) 1.280.410 1.350.32 0.26 
LDL (mmol/L) 4.191.180 3.620.94 0.003 
Triglycerides (mmol/L) 1.790.730 1.060.74 <0.001 
Glucose (mmol/L) 5.611.040 5.440.49 0.11 
hsCRP (mg/L)a 3.57 (1.2–7.12) 1.09 (0.58–2.04) <0.001 
GFR (mL/min/1.73 m2) 102.526.500 97.918.2 0.25 
β2M (µg/L) 1858.1472.800 1554.5277.90 <0.001 
Fetuin-A (µg/mL) 260.2±10600 0254.8±104.9 0.77 
AIx (%) 28800 1411 <0.001 
aPWV (m/s) 9.92.20 7.61.6 <0.001 
Current smoking, n (%) 64 (97) 2 (3) <0.001 
Medication, n (%)    
 Calcium channel blockers 10 (15.2) 0 (0) <0.001 
 ACE inhibitors 8 (12.1) 0 (0) <0.001 
 Angiotensin receptor blockers 5 (7.6) 0 (0) 0.006 
 Beta-blockers 2 (3) 0 (0) 0.16 
 Diuretics 2 (3) 0 (0) 0.16 
 Pentoxyfylline  25 (37.9%) 0 (0) <0.001 
 Aspirin 14 (21.2%) 0 (0) <0.001 
 Statins 6 (9.1%) 0 (0) 0.002 
 a indicates medians and interquartile ranges. 
53 
Table 9. Multiple regression model for the patients with aPWV as the dependent 
variable. 
Variable Regression coefficient Standard error P value 
β2M (µg/L)  0.002 <0.001 0.005 
Age (years)  0.084 0.038 0.031 
MAP (mmHg)  0.025 0.018 0.168 
R2 = 0.3, p<0.001, n=66. 
 
 
Table 10. Multiple regression model for the patients with β2M as the dependent 
variable. 
Variable Regression coefficient Standard error P value 
Fetuin-A (μg/mL) 1.655 0.409 <0.001 
aPWV (m/s) 51.729 21.485 0.019 
Age (years) 16.496 6.883 0.02 
GFR (mL/min/1.73m2) –3.772 1.809 0.041 
R2 = 0.5, p<0.001, n=66. 
 
 
Figure 8. Scatterplots of the functional and biochemical parameters for 66 patients and 
66 controls. The aPWV and β2M were significantly correlated for the patients (r=0.47, 
p<0.001) but not for the controls (r=0.14, p=0.26). 
 
14
54 
 
Figure 9. Scatterplots of the functional and biochemical parameters for 66 patients and 
66 controls. The β2M and fetuin-A levels were significantly correlated for the patients 
(r=0.46, p<0.001) but not for the controls (r=0.1, p=0.44). 
 
 
5.3. Association between aortic stiffness and severity 
of peripheral arterial disease (Papers III and IV) 
 
Relationship between ankle-brachial pressure index, aortic stiffness and 
vitamin D (Paper III) 
The characteristics of the patients with atherosclerosis are summarized in 
Table 4. We tested the hypothesis about whether increased arterial stiffness and 
decreased vitamin D levels are associated with more advanced atherosclerotic 
disease. In univariate analysis, there was almost significant correlation between 
ABPI and 25(OH)D (r=0.26, p=0.051). We evaluated the relationship between 
ABPI and the composite measure of aPWV and 25(OH)D. The patients were 
divided into 3 groups according to aPWV and 25(OH)D values. The first group 
comprised patients with aPWV below the median (9.7 m/s) and 25(OH)D above 
the median (15.2 ng/mL) (n=12). The second group consisted of patients with 
either aPWV>9.7 m/s and 25(OH)D>15.2 ng/mL or aPWV≤9.7 m/s and 
25(OH)D≤15.2 ng/mL (n=35). Patients in the third group had aPWV>9.7 m/s 
and 25(OH)D≤15.2 ng/mL (n=19). Twelve patients were omitted from the 
analysis, since the data on ABPI, aPWV or 25(OH)D were missing. There was a 
significant inverse association between ABPI and the composite measure of 
aPWV and 25(OH)D (p=0.03 by ANOVA). To illustrate this association, we 
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divided PAD patients into tertiles according to aPWV and 25(OH)D values. As 
shown in Figure 10, higher aPWV and lower 25(OH)D levels were related to 
lower ABPI.  
 
 
Figure 10. Relationship between ABPI and the tertiles of aPWV and 25(OH)D for the 
PAD patients (n=66). The aPWV has been adjusted for MAP.  
 
 
Relationship of aortic stiffness with angiographic score and ankle-brachial 
pressure index (Paper IV) 
The aPWV was positively correlated with AngSc (Figure 11) and negatively 
with ABPI (Figure 12) for the patient group. In multiple regression analysis, 
aPWV was independently associated with AngSc, log-OPN, log-oxLDL and 
eGFR for the patients and with age, log-oxLDL, heart rate and log-OPN in the 
controls (Table 7). In a multiple regression model containing only statistically 
significant variables, age, log-oxLDL, log-OPN and heart rate explained 37% of 
the variance in aPWV (p<0.001) for the controls. These associations persisted 
after correction for pack-years of smoking, ABPI, BMI, LDL, HDL, tri-
glycerides, glucose, heart rate and log-hsCRP.  
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Figure 11. Correlation between aPWV and AngSc (r=0.37, p=0.001) for the PAD 
patients. The aPWV has been adjusted for MAP. 
 
 
 
Figure 12. Correlation between aPWV and ABPI (r=–0.26, p=0.03) for the PAD 
patients. The aPWV has been adjusted for MAP. 
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5.4. Relationship of oxidative stress with arterial 
calcification and stiffness (Papers I and IV) 
Relationship between oxidative stress and arterial calcification (Paper I) 
The baseline characteristics of 69 patients and 68 healthy subjects are presented 
in Table 2. In univariate analysis, OPG was correlated with oxLDL (r=0.34, 
p=0.01) (Figure 13) for the patient group but not for the healthy subjects (data 
not shown). In multiple regression analysis, OPG correlated independently with 
aPWV and oxLDL for the patients (Table 11). In a multiple regression model 
containing only statistically significant variables, aPWV and oxLDL explained 
31% of the variance in OPG (p<0.001) in the PAD patients. 
 
Figure 13. Correlation between OPG and oxLDL for the PAD patients (r=0.34, 
p=0.01). 
 
Table 11. Multiple regression model for the patients and for the healthy subjects with 
OPG as the dependent variable.  
 Regression coefficient Standard error P value 
Patientsa     
  aPWV (m/s) 0.37 0.12 0.004 
  oxLDL (U/L) 0.02 0.01 0.03 
  HDL (mmol/L) 0.93 0.60 0.13 
  Age (years) 0.04 0.03 0.29 
  ABPI 0.88 0.82 0.29 
Controlsb    
  aPWV (m/s) 0.26 0.11 0.02 
  HDL (mmol/L) –0.96 0.56 0.09 
  Age (years) 0.04 0.03 0.2 
  oxLDL (U/L) –0.01 0.008 0.22 
a R2 value=0.48, p <0.00001, n=69. b R2 value=0.35; p <0.002, n=68. 
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Relationship between oxidative stress and aortic stiffness (Paper IV) 
The baseline characteristics of 79 PAD patients and 84 clinically healthy 
subjects are shown in Table 6. The aPWV correlated significantly with oxLDL 
(Figure 14) for the patients with PAD and for the controls. In multiple 
regression analysis, aPWV was independently associated with AngSc, log-OPN, 
log-oxLDL, eGFR and age for the patients and with age, log-oxLDL, log-OPN, 
and heart rate for the controls (Table 7). As shown in Figures 15 and 16, higher 
levels of OPN and oxLDL were related to higher aPWV values for both study 
groups. 
 
 
Figure 14. Correlation between aPWV and log-oxLDL for the patients (r=0.28, p=0.01) 
and for the control subjects (r=0.26, p=0.02). The aPWV has been adjusted for MAP. 
Filled dots represent the patients; empty dots represent the controls. Continuous line 
represents the regression line through the patient data; interrupted line represents the 
regression line through the control data. 
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Figure 15. Relationship between aPWV and the tertiles of OPN and oxLDL for the 
PAD patients. The aPWV has been adjusted for MAP. 
 
 
 
Figure 16. Relationship between aPWV and the tertiles of OPN and oxLDL for the 
controls. The aPWV has been adjusted for MAP. 
OPN (ng/mL) 
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6. DISCUSSION 
6.1. The role of vascular calcification  
in aortic stiffening 
The VCa may influence the clinical course of PAD (Guzman et al. 2008). The 
VCa leads to an increase in arterial wall thickness and reduction in conduit 
artery lumen area, which may promote arterial stiffening and impair distal tissue 
perfusion (Greenwald 2007). The presence and extent of VCa are predictors of 
critical limb ischaemia requiring amputation (Guzman et al. 2008) and subse-
quent vascular morbidity and mortality (Wilson et al. 2001; Rennenberg et al. 
2009). Recent research suggests that VCa is an active and complex process that 
involves numerous mechanisms responsible for calcium deposition in arterial 
wall (Jayalath et al. 2005). A growing body of evidence suggests that regulators 
of bone remodelling, such as OPG, OPN and vitamin D might play a major role 
in VCa and arterial stiffening. 
We have demonstrated that the patients with PAD had higher values of OPG 
as compared to the controls (Paper I). Similarly, several clinical studies have 
identified the relationship between elevated serum OPG and CAD, diabetic 
complications, heart failure, abdominal aortic aneurysm and CV mortality 
(Kiechl et al. 2006). In contrast, a recent cross-sectional study reported that OPG 
levels were not statistically different between patients with PAD and subjects 
without PAD (Koshikawa et al. 2009). However, Koshikawa and co-authors 
included subjects with hypertension and diabetes in the control group, whereas 
the control group in our study comprised clinically healthy individuals. Increa-
sed levels of OPG in patients with atherosclerosis may be explained by several 
mechanisms. As calcification is common within atherosclerotic plaque, elevated 
OPG levels could indicate an increased burden of atherosclerosis. Alternatively, 
increased OPG may represent a compensatory response to mitigate further 
vascular injury (Morony et al. 2008). Consistent with this hypothesis, OPG is 
known to inhibit apoptosis (Vitovski et al. 2007). As apoptotic debris may 
promote calcium deposition in the vascular wall, expression of OPG in the 
endothelium might be upregulated to inhibit apoptosis (Shroff et al. 2008b). 
The present study has also revealed that serum OPG is independently related 
to aPWV in the PAD patients and in apparently healthy subjects. Similarly, the 
association between circulating levels of OPG and aortic stiffness has been 
shown in patients with chronic kidney disease (Scialla et al. 2011) and in post-
menopausal women (Frost et al. 2008). The relationship between aortic 
stiffening and elevated serum OPG might be influenced by endothelial 
dysfunction. Previous research demonstrates that impaired endothelial function 
is associated with elevated serum OPG (Golledge et al. 2008) and increased 
arterial stiffness (Kals et al. 2006a). It might be that endothelial injury leads to 
arterial stiffening and upregulates the expression of OPG in endothelial cells 
(Shroff et al. 2008b).  
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Serum OPN is another important inhibitor of VCa that has been implicated 
in the pathogenesis of atherosclerosis (Momiyama et al. 2010; Waller et al. 
2010). Recent research indicates that plasma OPN levels are higher in patients 
with unstable angina than in those with stable angina or in control subjects 
(Soejima et al. 2006). Moreover, circulating OPN levels are elevated in patients 
with carotid atherosclerosis (Kurata et al. 2006). In Paper IV, we showed that 
patients with PAD had higher OPN as compared to controls, which is consistent 
with the results of a previous study (Koshikawa et al. 2009). However, the 
results of our study expand the findings of Koshikawa and co-authors, as the 
patients in our study were younger and free of diabetes (Koshikawa et al. 2009). 
Increased circulating OPN might have prognostic significance, as it has been 
demonstrated that OPN levels predict CV death, myocardial infarction, stroke 
and endovascular interventions in patients undergoing carotid surgery (de Kleijn 
et al. 2010).  
It is intriguing to hypothesize that OPN might be involved in the patho-
genesis of PAD. We have shown that aortic stiffness is independently asso-
ciated with serum levels of OPN in the patients with PAD as well as in the 
healthy subjects (Paper IV). This mechanistic insight is consistent with a 
previous observation that elevated OPN levels are independently associated 
with increased aortic stiffness in patients with rheumatoid arthritis (Bazzichi et 
al. 2009). The OPN might modulate aortic stiffness by stimulating proliferation 
of the VSMC and thickening of the media (Isoda et al. 2002). Moreover, animal 
models have highlighted the importance of OPN as an inducible inhibitor of 
vascular mineralization (Speer et al. 2002). Thus, the positive association 
between OPN and aortic stiffness may represent a protective increase in OPN 
aimed at limiting vascular damage.  
Previous research suggests that VCa is involved in the development of aortic 
stiffness and the subsequent pathogenesis of isolated systolic hypertension 
(Blacher et al. 2001; McEniery et al. 2009). Moreover, aortic stiffness is 
associated with the extent of coronary artery, aortic and valvular calcifications 
in patients with chronic kidney disease (Haydar et al. 2004; Raggi et al. 2007). 
In Paper III, we have demonstrated that aortic calcification is associated with 
aortic stiffness in patients with PAD and in healthy subjects. It could be that 
deposition of calcium in the aorta leads to aortic stiffening (Sigrist et al. 2007). 
Alternatively, increased arterial stiffness could lead to vessel wall damage and 
calcification (McEniery et al. 2009). Finally, it might be that both VCa (Wong 
et al. 2011) and arterial stiffness (McEniery et al. 2010; Astrand et al. 2011) are 
the consequences of age-related degenerative processes in the vasculature.  
Recently it has been reported that vitamin D is an important determinant of 
all-cause and CV mortality in high-risk patients (Pilz et al. 2011; Schierbeck et 
al. 2011) and in general population (Holick 2007; Melamed et al. 2008a). We 
have demonstrated that 25(OH)D levels are significantly lower in the PAD 
patients than in the controls (Paper III), which is consistent with the results of a 
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previous study (Reis et al. 2008). It could be that patients with PAD are less 
mobile and are therefore less affected by sun exposure (Melamed et al. 2008b). 
The role of vitamin D in the development of VCa is controversial. The 
effects of vitamin D on VCa appear to follow a biphasic pattern, with both 
excess and deficiency promoting its development (Shroff et al. 2008a). In our 
study, serum levels of 25(OH)D correlated positively with ACS in the PAD 
patients and negatively in the controls (Paper III). It could be that different 
localizations of calcium deposits in aortic wall were responsible for different 
patterns of correlation between aortic calcification and vitamin D seen among 
the study groups. Previous studies indicate that in patients with atherosclerosis 
mostly intimal calcification is seen (Verbeke et al. 2010). In contrast, medial 
calcification is associated with diabetes mellitus, end-stage renal disease and 
aging (Verbeke et al. 2010). Based on these observations, we hypothesized that 
a combination of intimal and medial calcification occurred in PAD patients, 
whereas age-related medial calcification was predominant in healthy subjects. 
Vitamin D could be involved in the regulation of arterial stiffness. Lower 
levels of 25(OH)D are independently associated with increased arterial stiffness 
in patients with chronic kidney disease (Patange et al. 2012) and in healthy 
subjects (Al Mheid et al. 2011). Vitamin D could influence arterial stiffness by 
modulating VSMC tone (Shan et al. 1993), inhibiting the renin-angiotensin 
system (Li et al. 2002), or by regulating the expression of a number of proteins 
present in the arterial wall, such as elastin, collagen, myosin and matrix metallo-
proteinase (Norman et al. 2005). We have demonstrated borderline association 
between vitamin D and aortic stiffness in clinically healthy subjects (Paper III). 
The lack of statistically significant association between these parameters might 
be attributable to small sample size.  
 
 
6.2. β2-microglobulin as a predictor of aortic  
stiffness in patients with peripheral arterial disease 
The β2M has recently emerged as a biomarker of atherosclerosis (Amighi et al. 
2011). It has been shown that circulating β2M levels are increased in PAD 
patients and correlate with severity of disease as assessed by ABPI or treadmill 
testing (Wilson et al. 2007; Fung et al. 2008). Importantly, in patients with 
CAD, β2M levels were higher in the patients who also had PAD as compared to 
subjects without PAD (Wilson et al. 2007). This finding indicates that β2M 
predicts the presence of PAD even in patients with high CV risk. Consistently 
In conclusion, we have shown that aortic stiffness is independently  
associated with serum levels of OPG, OPN and 25(OH)D as well as aortic  
calcification in patients with symptomatic PAD and in apparently healthy 
subjects. Assessment of aortic stiffness as well as of the biochemical and 
structural markers of VCa could provide additional insight into the pathogenesis 
of PAD.  
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with these data, we demonstrated that plasma levels of β2M are elevated in 
patients with PAD as compared with controls (Paper II). However, we did not 
find significant association between β2M levels and ABPI in either of the study 
groups. The discrepancy in the results between our study and the previous one 
(Wilson et al. 2007) may be explained by the fact that Wilson and the co-
authors studied both men and women, whereas all participants in our study were 
men. Moreover, the PAD patients in the study by Wilson and the co-authors had 
significantly lower eGFR compared to the patients in our study. As β2M is 
mainly eliminated by glomerular filtration (Donadio et al. 2001), the difference 
in eGFR between the studies may have affected the association between β2M 
and ABPI. 
Aortic stiffness is another important determinant of CV risk (Mattace-Raso 
et al. 2006; Vlachopoulos et al. 2010). We have demonstrated increased aortic 
stiffness and wave reflection in patients with PAD compared with controls 
(Papers I–IV). This finding supports the results of previous studies (Cheng et al. 
2002; Kals et al. 2006a; Tsuchikura et al. 2010). Research data suggest that 
aortic stiffness is a major contributor to atherosclerosis. Aortic stiffening leads 
to an increase in systolic BP and a widening of pulse pressure, which promotes 
arterial wall damage and accelerates progression of the atherosclerotic process 
(Boutouyrie et al. 2002). Moreover, increased aortic stiffness decreases 
diastolic BP and is related to impaired blood flow in the arteries of the lower 
extremities (Tsuchiya et al. 2005). Finally, aortic stiffness influences functional 
capacity in patients with atherosclerosis. In PAD patients, increased aPWV is 
independently associated with slower gait speed (Watson et al. 2011), whereas 
reduction of PWV by an ACE inhibitor is significantly related to improved 
performance on the treadmill walk test (Ahimastos et al. 2008).  
We found independent association between aortic stiffness and plasma β2M 
in patients with PAD (Paper II). Accordingly, β2M is independently associated 
with arterial stiffness in general population (Saijo et al. 2005). However, we did 
not find significant association between β2M and aortic stiffness in apparently 
healthy subjects. Several explanations could be given for the discrepancies 
between the above study (Saijo et al. 2005) and the present one. Saijo and co-
authors assessed arterial stiffness by baPWV, which describes the properties of 
both the aorta and the lower limb arteries. However, we used aPWV as a „gold 
standard” measure of arterial stiffness (Laurent et al. 2006). Moreover, both 
men and women participated in the above study, whereas all the participants of 
our study were men. As gender is an important determinant of aortic stiffness 
(Sonesson et al. 1993), the gender difference could account for the discrepancy 
between the results of the studies. 
There are several possible linking mechanisms between β2M and aortic 
stiffness. Chronic inflammation is involved in the pathogenesis of vascular 
remodelling and atherosclerosis (Hassoun et al. 2009; Recio-Mayoral et al. 
2011). Previous studies have shown that CRP is related to aortic stiffness 
(Yasmin et al. 2004) and wave reflection (Kampus et al. 2006) in apparently 
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healthy individuals. Moreover, a combination of increased CRP and β2M is 
significantly associated with elevated arterial stiffness in healthy subjects (Saijo 
et al. 2005). Thus, inflammation may be a potential link between β2M and aortic 
stiffness. In contrast, neither β2M nor aPWV was associated with hsCRP in our 
study, which might be explained by relatively small sample size. Alternatively, 
renal function could modulate the association of β2M with aortic stiffness. It has 
been reported that both β2M (Jovanovic et al. 2003) and aPWV (Mourad et al. 
2001; Kawamoto et al. 2008) are related to eGFR. Moreover, aPWV and β2M 
are independent predictors of all-cause mortality in patients with end-stage renal 
disease (Blacher et al. 1999; Okuno et al. 2009). Consistently with these data, 
we demonstrated that eGFR is inversely related to β2M and aPWV in patients 
with PAD and in controls. These findings suggest that β2M might be important 
in renal-induced vascular stiffening. Finally, VCa may provide a mechanistic 
link between β2M and aortic stiffness. We have shown that fetuin-A correlates 
independently with β2M in the patient group (Paper II). Fetuin-A is an important 
inhibitor of ectopic calcification and is inversely related to coronary (Jung et al. 
2011) and valvular (El-Shehaby et al. 2010) calcification in haemodialysis 
patients. Furthermore, accumulation of β2M amyloid is associated with mitral 
valve calcification in haemodialysis patients (Takayama et al. 2001). It would 
be intriguing to hypothesize that VCa increases aortic stiffness and elevates 
circulating levels of β2M and fetuin-A.  
To summarise, we have demonstrated that β2M is independently associated 
with aortic stiffness in patients with PAD. This finding suggests that β2M may 
be related to the stiffening of the aorta in advanced atherosclerosis. Our study 
supports the use of β2M as a biomarker of atherosclerosis. 
 
 
6.3. Aortic stiffness is a determinant of severity  
of peripheral arterial disease 
The PAD is complicated by high rate of coronary and cerebral events 
(McDermott et al. 2001). However, as the majority of PAD patients do not 
manifest the classic symptomatology, early diagnosis and assessment of CV risk 
in these patients is a significant clinical challenge (Hirsch et al. 2007).  
The ABPI is an established clinical tool for assessing presence and severity 
of PAD (Guo et al. 2008). We have demonstrated that increased aPWV and 
lower levels of 25(OH)D are related to lower ABPI values in patients with PAD 
(Paper III). Similarly, a recent study has shown that reduced arterial compliance 
is related to decreased ABPI in elderly subjects (Lind 2011). However, Lind 
assessed arterial compliance by ultrasound as the distensibility of the carotid 
artery, whereas we evaluated aortic stiffness by aPWV. We did not find any 
association between ABPI and aPWV in clinically healthy subjects, which is 
consistent with the results of a previous study (Rabkin et al. 2012). 
Interestingly, a recent study has reported that ABPI is positively associated with 
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baPWV and bkPWV in non-diabetic PAD patients (Khandapour et al. 2009). 
However, baPWV and bkPWV characterize wave propagation not only along 
the aorta but also along the lower-extremity arteries. Therefore, presence of 
stenoses or occlusions in the lower-extremity arteries affects the propagation of 
pulse wave (Motobe et al. 2005), and hence modulates the relationship between 
aPWV and ABPI.  
There are several lines of evidence suggesting that vitamin D may have a 
protective role in CV disease. Vitamin D improves endothelial function in 
patients with diabetes (Sugden et al. 2008). Moreover, vitamin D has been 
shown to be an inhibitor of the renin-angiotensin system (Li et al. 2002). A 
large population-based study has reported that ABPI is positively associated 
with 25(OH)D levels in apparently healthy Caucasian subjects (Reis et al. 
2008). Furthermore, lower serum 25(OH)D levels are associated with higher 
prevalence of PAD (Melamed et al. 2008b). In our study, a borderline corre-
lation was noted between ABPI and 25(OH)D in patients with PAD, which did 
not reach statistical significance, probably because of the small number of 
subjects. 
The AngSc provides information about the severity and distribution of 
atherosclerotic lesions in the lower-extremity arteries (Van der Feen et al. 
2002). In Paper IV, we have demonstrated that aPWV is independently related 
to AngSc in PAD patients, suggesting that aortic stiffness is related to the grade 
of atherosclerosis in the lower extremity arteries. There are several possible 
explanations for the relationship between arterial stiffness and atherosclerosis.  
It could be hypothesized that VCa influences the association between arterial 
stiffening and atherosclerosis. In our study, serum levels of calcification 
inhibitor OPN were positively correlated with AngSc and aPWV in patients 
with atherosclerosis (Paper IV). As the expression of OPN is increased at sites 
of calcification in atherosclerotic plaques (Fitzpatrick et al. 1994) and predicts 
aortic stiffening in patients with rheumatoid arthritis (Bazzichi et al. 2009), it 
might provide a mechanistic link between arterial stiffening and atherosclerosis. 
Inflammation is an important determinant of the formation of atherosclerotic 
plaques (Derlin et al. 2011) and has been implicated in the process of arterial 
stiffening (De Silva et al. 2008). Previous studies have reported that CRP levels 
are associated with arterial stiffness in patients with rheumatoid arthritis 
(Provan et al. 2011), in women with systemic lupus erythematosus (Bjarnegård 
et al. 2006) and in apparently healthy individuals (Kampus et al. 2004; Yasmin 
et al. 2004). Furthermore, CRP is predictive of disease progression, all-cause 
and CV mortality in patients with PAD (Van Der Meer et al. 2002; Vidula et al. 
2008). Therefore, inflammation may influence the relationship between aortic 
stiffening and atherosclerosis. 
Endothelial dysfunction is another potential link between arterial stiffening 
and atherosclerosis (Halcox et al. 2002; Figueiredo et al. 2012). Endothelial 
dysfunction has been found to be associated with severity of PAD (Silvestro et 
al. 2003) and predicts adverse CV events in these patients (Brevetti et al. 2003). 
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Impaired endothelial function could contribute to progression of PAD by 
impairing blood flow responses to ischaemia and by promoting vasospasm, 
plaque rupture and thrombosis (Vita and Hamburg 2010). Although we did not 
assess endothelial function in the present study, we have previously reported 
that endothelial dysfunction is related to increased arterial stiffness in patients 
with symptomatic PAD (Kals et al. 2006a). 
Alternatively, both aortic stiffening (Astrand et al. 2011) and atherosclerosis 
(Van Popele et al. 2001) might be the consequences of aging. In our study, 
aortic stiffness was significantly correlated with age in both study groups. 
However, an independent association between AngSc and aPWV remained 
significant after adjustment for age.  
To summarise, increased aortic stiffness and lower vitamin D levels are 
related to decreased ABPI in the PAD patients. Moreover, aPWV is 
independently associated with AngSc in the patients with PAD. Given that both 
vitamin D (Schierbeck et al. 2011) and aortic stiffness (Laurent et al. 2001) 
have been associated with an increased risk of CV events, assessment of these 
parameters may be used in risk stratification and in assessment of the rate of 
progression of PAD. 
 
 
6.4. Aortic stiffness, vascular calcification  
and oxidative stress 
Pathological OxS is a key factor in the pathogenesis of atherosclerosis. Both 
oxLDL (Maziere et al. 2010; Parthasarathy et al. 2010) and 8-iso-prostaglandin 
F2α (Mueller et al. 2004; Schwedhelm et al. 2004) have been recognized as 
reliable markers of OxS. The oxLDL is involved in the initiation and 
progression of atherosclerosis, and contributes to functional and structural 
alterations of large arteries (Ehara et al. 2001; Andersson et al. 2009). We have 
shown that serum oxLDL is significantly higher in PAD patients than in 
controls (Papers I and IV), which is in accordance with the results of previous 
research (Mueller et al. 2004; Kals et al. 2006b). However, in these studies, 
OxS was assessed by 8-iso-prostaglandin F2α, whereas oxLDL was measured in 
the present study. The oxLDL is not only a marker of OxS but may also 
promote progression of atherosclerosis. It has been shown that unstable carotid 
plaques have a much greater content of oxLDL than stable carotid plaques 
(Nishi et al. 2002). Furthermore, plasma oxLDL are higher in patients with 
unstable angina and correlate with the incidence of angiographically complex 
coronary plaques (Anselmi et al. 2006).  
We detected no association between serum oxLDL and ABPI in either of the 
study groups (Paper IV). Similarly, a prior study did not find any association 
between circulating oxLDL and severity of atherosclerosis in patients with 
symptomatic PAD (Rosoky et al. 2010). There are several possible explanations 
for the lack of association between oxLDL and ABPI. It could be that 
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circulating oxLDL has a better predictive value at early stages of atherosclerosis 
rather than in patients with established atherosclerosis (Rosoky et al. 2010). 
Alternatively, circulating oxLDL levels increase in the acute phase of ischaemia 
and might not reflect disease severity in patients with stable chronic 
atherosclerosis. Consistent with this hypothesis, oxLDL levels increase rapidly 
in patients suffering myocardial infarction and decrease towards baseline levels 
over the following 7 months (Tsimikas et al. 2003).  
Profound OxS has also been implicated in arterial stiffening. An earlier study 
has established that urinary 8-iso-prostaglandin F2a concentration is related to 
the indices of arterial elasticity in patients with PAD (Kals et al. 2008). In the 
present study (Paper IV), we expanded previous research by demonstrating an 
independent association between serum oxLDL and aortic stiffness in PAD 
patients and in healthy subjects. Similarly, cystine, which is a non-free radical 
marker of OxS, has been associated with aortic stiffness in apparently healthy 
subjects (Patel et al. 2011).  
Aortic stiffness and OxS might be linked by different pathophysiological 
mechanisms. First, endothelial dysfunction may influence the relationship bet-
ween increased production of reactive species and aortic stiffening. Prior studies 
indicate that oxLDL contributes to endothelial dysfunction (Wang et al. 2011) 
and activates apoptosis in the endothelial cells (Dimmeler and Zeiher 2000). 
Decreased bioavailability of NO could lead to vasoconstriction and aortic 
stiffening (Kals et al. 2006a; Loffredo et al. 2007). Second, profound OxS may 
promote degradation of elastin by matrix metalloproteinases and reduce the 
elasticity of the aortic wall (Rajagopalan et al. 1996; Galis and Khatri 2002). 
Accordingly, matrix metalloproteinase-2 is positively associated with aPWV in 
hypertensive patients (Yasmin et al. 2005). Moreover, experimental research 
indicates that OxS enhances collagen secretion by aortic smooth muscle cells, 
and increases therefore aortic stiffness (Zhou et al. 2011).  
Apart from influencing aortic stiffness, profound OxS may also contribute to 
VCa (Mody et al. 2001). We have demonstrated that oxLDL levels are 
independently related to serum OPG in patients with atherosclerosis (Paper I). 
Thus, OxS might be related to VCa in PAD patients. Accordingly, elevated 
OPG levels are associated with surrogate markers of OxS in patients with 
chronic kidney disease (Matsubara et al. 2009). In addition, a recent animal 
study has reported that increased production of reactive species is related to 
overexpression of OPG in the vascular tissue (Aydin et al. 2011). It has been 
suggested that high levels of OPG may represent an inadequate compensatory 
response aiming at limiting vascular injury in patients with atherosclerosis (Van 
Campenhout and Golledge 2009). Thus, our finding that OPG is associated with 
oxLDL in PAD patients could suggest that high-grade OxS is related to VCa in 
advanced atherosclerosis.  
The association between serum OPG and oxLDL levels can be explained by 
several mechanisms. As OPG is highly expressed in VSMC (Zhang et al. 2002), 
the fact that reactive species stimulate hypertrophy and proliferation of VSMC 
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(Dimmeler and Zeiher 2000) may provide a mechanistic link between elevated 
levels of OPG and oxLDL. An alternative possibility is that the relationship 
between OxS and VCa can be modulated by apoptosis. The ROS are known to 
induce apoptotic cell death in endothelial cells (Dimmeler and Zeiher 2000). 
Apoptotic bodies of endothelial and foam cells might provide a suitable 
microenvironment for VCa (Shao et al. 2006). 
The association of oxLDL levels with aPWV and OPG in PAD patients 
indicates that oxLDL may be related to the pathogenesis of aortic stiffening and 
calcification in advanced atherosclerosis. In addition, serum oxLDL is 
associated with aPWV in controls, suggesting that OxS might be implicated in 
aortic stiffening in apparently healthy subjects. 
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7. CONCLUSIONS 
1. Aortic pulse wave velocity and serum levels of osteoprotegerin and oxidized 
low-density lipoprotein were increased in the patients with symptomatic 
peripheral arterial disease as compared to the healthy subjects. Serum 
osteoprotegerin levels were significantly associated with aortic pulse wave 
velocity in the patients with peripheral arterial disease as well as in the 
healthy subjects. In addition, serum osteoprotegerin was related to oxidized 
low-density lipoprotein in the patient group. These findings would suggest 
that aortic stiffness is related to calcification in patients with atherosclerosis 
and in healthy subjects.  
2. Plasma β2-microglobulin was significantly higher among the patients with 
peripheral arterial disease. The β2-microglobulin levels were independently 
associated with aortic pulse wave velocity and fetuin-A level in the patients 
with symptomatic peripheral arterial disease. These findings indicate that the 
inflammatory biomarker β2-microglobulin is associated with aortic stiffness 
and with calcification in patients with atherosclerosis. 
3. The patients with peripheral arterial disease had significantly higher aortic 
calcification score but lower vitamin D levels compared with the controls. 
The extent of aortic calcification was independently associated with 
increased aortic pulse wave velocity in the patients with peripheral arterial 
disease and in the clinically healthy subjects. Aortic calcification score 
showed positive correlation with vitamin D levels in the patient group and 
negative correlation among the control subjects. These findings suggest that 
calcification of the aorta is related to increased aortic stiffness in patients 
with atherosclerosis and in healthy subjects. The extent of aortic calcification 
is positively related to serum levels of vitamin D in patients with athero-
sclerosis and negatively related to vitamin D levels in healthy subjects. 
4. Osteopontin levels were significantly higher in the patients with sympto-
matic peripheral arterial disease compared with the controls. Aortic pulse 
wave velocity was independently related to serum levels of osteopontin and 
oxidized low-density lipoprotein in the patients with atherosclerosis and in 
the clinically healthy subjects. These findings indicate that aortic stiffness is 
associated with calcification and oxidative stress in patients with athero-
sclerosis and in controls. 
5. Aortic pulse wave velocity was independently associated with angiographic 
score in the patients with peripheral arterial disease, suggesting that aortic 
stiffness is related to the distribution and severity of atherosclerotic lesions 
in the lower extremity arteries in patients with the established diagnosis of 
peripheral arterial disease.  
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SUMMARY IN ESTONIAN 
Arterikahjustuste biokeemiline,  
funktsionaalne ja strukturaalne  
profileerimine ateroskleroosi korral 
Arterite jäikus iseloomustab arterite laienemisvõimet vererõhu tõusu mõjul. 
Jäigad arterid tõstavad vasaku vatsakese järelkoormust, mis omakorda põhjus-
tab vasaku vatsakese hüpertroofiat ja suurendab müokardi hapnikuvajadust. 
Lisaks langetab arterite jäigenemine diastoolset vererõhku ja vähendab veelgi 
koronaarperfusiooni, mis viib circulus vitiosus’e tekkeni. Pulsilaine leviku 
kiiruse registreerimine aordis on tänapäeval arteriaalse jäikuse hindamise kuld-
standard. Aordi suurenenud jäikus ennustab iseseisvalt üld- ja kardiovasku-
laarset suremust kõrge riskiga patsientidel ja üldrahvastikus. Tuginedes mitmete 
rahvastikupõhiste uuringute andmetele, on kindlaks tehtud pulsilaine kiiruse 
referentsväärtused. Euroopa Hüpertensiooni Ühingu ja Euroopa Kardioloogide 
Seltsi hüpertensiooni ravijuhendis peetakse pulsilaine kiiruse suurenemist üle 
12 m/s subkliinilise organkahjustuse markeriks.  
Arterite kaltsifikatsioonil on oluline roll ateroskleroosi patogeneesis. Mitmed 
uuringud on näidanud, et arterite kaltsifikatsioon ja jäigenemine on omavahel 
seotud, kuid nende muutuste täpne vahekord aterogeneesis on veel lõplikult 
teadmata. Arterite kaltsifikatsioon haarab arterite sise- ja/või keskkesta. Sise-
kesta kaltsifikatsioon esineb eeskätt ateroskleroosi korral. Seevastu meedia 
kaltsifikatsioon (arterioskleroos) on seotud diabeedi, kroonilise neerupuudu-
likkuse, hüpertensiooni ja vananemisega. Nii eksperimentaalsete kui kliiniliste 
uuringute tulemused viitavad sellele, et kaltsiumi ladestumine aordi seinas on 
reguleeritud mitmete kaltsifikatsiooni aktivaatorite ja inhibiitoritega. 
Osteoprotegeriin on kaltsifikatsiooni inhibiitor, mis kuulub tuumornekroosi-
faktori retseptorite perekonda. Osteoprotegeriini toodetakse luudes, endoteelis 
ja veresoonte silelihasrakkudes. Hiirtel on osteoprotegeriini puudulikkus seotud 
raskekujulise osteoporoosi ja kaltsiumi ladestumisega aordi ja neeruarterite 
seinte keskkestas. Seega loomkatsete tulemused viitavad sellele, et osteoprote-
geriinil on protektiivne roll ateroskleroosi korral. Seevastu inimuuringud on 
näidanud, et osteoprotegeriini taseme suurenemine on seotud südame isheemia-
tõve, arterite kaltsifikatsiooni, diabeetilise mikroangiopaatia ja alajäsemete 
arterite ateroskleroosiga. 
Osteopontiin kuulub samuti kaltsifikatsiooni inhibiitorite hulka. Loom-
mudelites on näidatud, et osteopontiini defitsiit on seotud arterite väljendunud 
kaltsifikatsiooniga. Tänapäeval on kindlaks tehtud, et osteopontiin osaleb põle-
tiku poolt vahendatud aterosklerootilises protsessis. Osteopontiini toodetakse 
aterosklerootilistes naastudes, mis soodustab makrofaagide tungimist subendo-
teliaalsesse kihti ning põletikuliste tsütokiinide produktsiooni. Seerumi osteo-
pontiini tase on seotud südame isheemiatõve raskusastmega ja ennustab ise-
seisvalt kardiovaskulaarsete tüsistuste teket. 
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Vitamiin D on oluline lüli luu ainevahetuse ning südame- ja veresoonkonna-
haiguste vahel. Vitamiin D roll arterite kaltsifikatsiooni tekkimises ja arene-
mises on vastuoluline. Uuringute tulemused viitavad sellele, et nii vitamiin D 
defitsiit kui liigsus on seotud arterite väljendunud kaltsifikatsiooniga. Lisaks 
kaltsiumi ainevahetuse regulatsioonile vähendab vitamiin D reniin-angiotensiin-
süsteemi aktiivsust ja pärsib põletikuliste tsütokiinide sekretsiooni. 
Tänapäeval on kindlaks tehtud, et põletikul on keskne roll ateroskleroosi 
patogeneesis. Suured prospektiivsed uuringud on näidanud, et C-reaktiivse 
valgu taseme suurenemine ennustab sõltumatult teistest riskifaktorites kardio-
vaskulaarset suremust nii üldrahvastikus kui suure riskiga patsientidel.  
β2-mikroglobuliin osaleb samuti põletikulise protsessi regulatsioonis. β2-mikro-
globuliini sisaldus seerumis on suurenenud infektsioonide, autoimmuunhaiguste 
ja ateroskleroosi korral ning on üldsuremuse riski sõltumatuks teguriks. 
Tugev kestev oksüdatiivne stress on tähtis aterosklerootilise protsessi vallan-
daja ja edasiviija. Reaktiivsete osakeste liigteke kahjustab endoteeli funktsiooni, 
suurendab arterite jäikust, soodustab vahtrakkude teket ja veresoonte silelihas-
rakkude proliferatsiooni. Oksüdeeritud madala tihedusega lipoproteiin on oksü-
datiivse stressi marker, mis omab tugevat proaterogeenset toimet ja ennustab 
kardiovaskulaarseid tüsistusi ja suremust. 
Alajäsemete arterite ateroskleroos on levinud haigus, mis avaldub vahelduva 
lonkamise ja rahuolekuvaludena, kuid võib raskematel juhtudel tüsistuda 
gangreeniga. Samuti on nendel haigetel oluliselt suurenenud ka müokardi- ja 
ajuinfarkti tekke risk. Varasemate uuringute tulemused viitavad sellele, et süs-
teemne põletik, tugev oksüdatiivne stress ja arterite kaltsifikatsioon ning 
jäigenemine võivad mõjutada alajäseme arterite ateroskleroosi kliinilist kulgu. 
Ometi on vähe andmeid nende tegurite vaheliste seoste kohta alajäseme arterite 
ateroskleroosi korral.  
 
Uurimuse eesmärgid 
Käesoleva töö eesmärgiks oli uurida aordi jäikust (funktsionaalne profileeri-
mine), aordi kaltsifikatsiooni ja angiograafilist skoori (strukturaalne profileeri-
mine); samuti hinnata kaltsifikatsiooni, põletiku ja oksüdatiivse stressi biomar-
kerite taset (biokeemiline profileerimine) alajäsemete arterite ateroskleroosiga 
patsientidel ja kliiniliselt tervetel uuritavatel. Lisaks uurida arterikahjustuste 
funktsionaalse, biokeemilise ja strukturaalse profiili vahelist seost ja hinnata 
nende potentsiaalset rolli ateroskleroosi korral.  
 
Uurimuse täpsed eesmärgid olid järgmised: 
1. Võrrelda pulsilaine kiirust aordis (funktsionaalne profileerimine) ja 
osteoprotegeriini ning oksüdeeritud madala tihedusega lipoproteiini seerumi 
taset (biokeemiline profileerimine) ja hinnata nendevahelist seost alajäse-
mete arterite ateroskleroosiga patsientidel ja kliiniliselt tervetel uuritavatel. 
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2. Määrata pulsilaine kiirust aordis (funktsionaalne profileerimine), β2-mikro-
globuliini ja fetuiin-A plasma taset (biokeemiline profileerimine) alajäse-
mete arterite ateroskleroosiga patsientidel ja kliiniliselt tervetel uuritavatel ja 
testida, kas β2-mikroglobuliini suurenenud tase on seotud aordi jäigenemise 
ja fetuiin-A taseme suurenemisega. 
3. Võrrelda aordi kaltsifikatsiooni skoori (strukturaalne profileerimine), pulsi-
laine kiirust aordis, Doppler-indeksit (funktsionaalne profileerimine) ja 
vitamiin D seerumi taset (biokeemiline profileerimine) ning hinnata nende 
parameetrite vahelist seost alajäsemete arterite ateroskleroosiga patsientidel 
ja kliiniliselt tervetel uuritavatel. 
4. Uurida pulsilaine kiirust aordis (funktsionaalne profileerimine), osteopontiini 
ning oksüdeeritud madala tihedusega lipoproteiini seerumi taset (biokeemi-
line profileerimine) ja hinnata funktsionaalse ja biokeemilise profiili vahelist 
seost alajäsemete arterite ateroskleroosiga patsientidel ja kliiniliselt tervetel 
uuritavatel. 
5. Hinnata pulsilaine kiiruse aordis (funktsionaalne profileerimine) ja angio-
graafilise skoori (strukturaalne profileerimine) vahelist seost alajäsemete 
arterite ateroskleroosiga patsientidel. 
 
Uuringute meetodid 
Uuriti 79 alajäsemete arterite ateroskleroosiga meespatsienti (II – IV staadium 
Fontaine järgi) ja 84 kliiniliselt tervet meest. Aordi jäikust hinnati pulsilaine 
kiiruse registreerimise kaudu Tartu Ülikooli Kardioloogiakliiniku Endoteeli 
Keskuses. Kaltsifikatsiooni, põletiku ja oksüdatiivse stressi biomarkerite tase 
määrati Tartu Ülikooli Biokeemia instituudis ja Sihtasutus Tartu Ülikooli 
Kliinikumi Ühendlaboris. Aordi kaltsifikatsiooni skoor ja angiograafiline skoor 
hinnati SA TÜK Radioloogiakliinikus. 
 
Tulemused ja järeldused 
1. Pulsilaine kiirus aordis ja osteoprotegeriini ning oksüdeeritud madala tihe-
dusega lipoproteiini seerumi tase olid suurenenud alajäsemete arterite atero-
skleroosiga patsientidel. Osteoprotegeriini seerumi tase oli seotud pulsilaine 
kiirusega aordis nii alajäsemete arterite ateroskleroosiga patsientidel kui ka 
kliiniliselt tervetel uuritavatel. Lisaks sellele esines statistiliselt oluline seos 
osteoprotegeriini ja oksüdeeritud madala tihedusega lipoproteiini sisalduse 
vahel ateroskleroosiga patsientide rühmas. Saadud informatsioon näitab, et 
aordi jäikus on seotud kaltsifikatsiooniga nii ateroskleroosiga patsientidel kui 
ka tervetel inimestel. 
2. β2-mikroglobuliini plasma tase oli suurenenud alajäsemete arterite atero-
skleroosiga patsientidel. β2-mikroglobuliini tase oli sõltumatult seotud pulsi-
laine kiirusega aordis ja fetuiin-A tasemega ateroskleroosiga patsientidel. 
Antud tulemused viitavad võimalusele, et põletiku marker β2-mikroglobuliin 
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on seotud nii aordi jäikusega kui ka kaltsifikatsiooniga ateroskleroosiga 
haigetel. 
3. Alajäsemete arterite ateroskleroosiga patsientidel oli suurenenud aordi kaltsi-
fikatsiooni skoor, kuid vähenenud vitamiin D sisaldus seerumis. Aordi 
kaltsifikatsiooni skoor oli sõltumatult seotud aordi pulsilaine kiirusega nii 
ateroskleroosiga haigetel kui ka kontrollrühma uuritavatel. Lisaks oli aordi 
kaltsifikatsiooni skoor seotud vitamiin D taseme suurenemisega ateroskle-
roosiga haigetel, kuid vitamiin D taseme vähenemisega tervetel inimestel. 
Uuringu tulemustest võib järeldada, et aordi kaltsifikatsioon on seotud nii 
aordi jäikuse kui vitamiin D tasemega nii ateroskleroosiga haigetel kui ka 
tervetel inimestel.  
4. Osteopontiini tase oli suurenenud alajäsemete arterite ateroskleroosiga hai-
getel. Pulsilaine kiirus aordis oli sõltumatult seotud osteopontiini ja oksü-
deeritud madala tihedusega lipoproteiini seerumi tasemega ateroskleroosiga 
haigetel ja kontrollrühma uuritavatel. Saadud informatsioon näitab, et aordi 
jäikus on seotud kaltsifikatsiooni ja oksüdatiivse stressiga nii ateroskle-
roosiga patsientidel kui ka tervetel inimestel. 
5. Pulsilaine kiirus aordis on sõltumatult seotud angiograafilise skooriga ala-
jäsemete arterite ateroskleroosiga patsientidel. Antud tulemus näitab, et aordi 
jäikus on seotud aterosklerootilise kahjustuse ulatuse ja raskusastmega ala-
jäsemete arterite ateroskleroosiga haigetel.  
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